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Abstract
Connexin26 (Cx26) and Cx30 facilitate gap junctional intercellular communication (GJIC) in
the epidermis and are linked to several syndromic skin diseases. We investigated 5 diseaselinked Cx26 mutants and demonstrated that the severity and extent of disease can be predicted
from the gain- or loss-of function properties of each mutant, as well as the ability to induce
cell death. We also used transgenic mice expressing S17F Cx26 (linked to keratitis-ichthyosisdeafness syndrome) or A88V Cx30 (linked to Clouston Syndrome) to investigate the
pathophysiology these skin diseases. We demonstrated that S17F Cx26, but not A88V Cx30,
promotes palmoplantar keratoderma by disrupting keratinocyte differentiation. Primary
keratinocyte cultures from these mice demonstrated the mutants can also affect gap junction
intercellular communication and cell migration. Lastly, we showed that mutant mice retain
most wound healing properties. Together, we suggest that syndromic mutants often display
gain-of-function properties and can disrupt keratinocyte differentiation in the epidermis.
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Chapter 1
1.1 Introduction
1.1.1 Structure, Function and Life-Cycle of Connexins and Gap Junctions
Gap junctions are multimeric transmembrane channels that allow adjacent cells to
communicate via the exchange of ions and small molecular messengers less than 1 kDa
(Alexander and Goldberg, 2003). Gap junctions and their individual connexin monomers have
been studied extensively since their discovery and characterization in the 1960’s (Revel and
Karnovsky, 1967). Cellular communication through gap junction channels plays an important
role in cell physiology and these molecules have proven indispensable to human health (Garcia
et al., 2016b). Connexins are 4-pass transmembrane proteins that can be found in nearly all
cell types in humans (Laird, 2006). Every connexin molecule contains cytosolic amino (NT)
and carboxy termini (CT), 2 extracellular loops (E1, E2), and one intracellular loop (IL) which
serve specific roles to make a functional gap junction channel with various properties of
molecular selectivity, channel gating, docking compatibility, and trafficking (Yeager and
Harris, 2007). For example, the crystal structure of the Cx26 channel demonstrates that the
NT can be located inside the pore suggesting it acts like a plug controlling channel gating and
molecular selectivity (Maeda et al., 2009). Furthermore, Cx26 has a smaller pore size
compared to other connexins (e.g. Cx43) which restricts molecular permeability (Weber et al.,
2004).
Connexins are named according to their molecular weight in kDa: for example, connexin26
(Cx26) is approximately 26 kDa. They are organized into compatibility subgroups in which
members can oligomerize to form mixed channels that have distinct channel properties from
channels composed of the individual connexin types; for example Cx26 and Cx30 can intermix
in connexons and gap junctions (Richard, 2000). Homomeric and heteromeric channels differ
because they are composed of one or multiple connexin types, respectively (Richard, 2000).
This variability dramatically increases the number of channel possibilities and intercellular
communication characteristics in cells expressing multiple connexins – further reinforcing
their complexity in cellular communication.
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Connexins are co-translationally inserted into the endoplasmic reticulum and travel to the
Golgi apparatus where many oligomerize to form connexons (Musil and Goodenough, 1993).
Small vesicles containing connexons traffic and fuse with the plasma membrane where they
may function as un-docked hemichannels to couple the cell to the extracellular milieu
(Goodenough and Paul, 2003). When a connexon docks with another from an adjacent cell, a
gap junction channel is formed, which allows for signaling molecules to pass between the
cytosol of both cells in a process called gap junctional intercellular communication (GJIC)
(Goodenough and Paul, 2009). Gap junction channels often tightly cluster in the plasma
membrane to form highly organized structures called gap junction plaques which create an
appositional region with a high degree of cytosolic coupling. Some connexins can be
phosphorylated to influence channel function (Lampe and Lau, 2004) or bind with any number
of intracellular proteins suggesting they may have additional non-channel functions (Laird,
2006). For example, the C-terminus of Cx43 is known to bind to several intracellular proteins
including a specific domain of the zona-occludens-1 protein which is best known to be
involved in the formation of tight junctions (Giepmans and Moolenaar, 1998; Toyofuku et al.,
1998). These findings suggest gap junctions at the membrane may also support intercellular
adhesion in addition to communication (Prochnow and Dermietzel, 2008). Gap junction
plaques can vary greatly in size (Zampighi et al., 1989) and composition wherein different
channel types are known to mix, or form separate clusters within a larger combined plaque
(Kelly et al., 2015). Gap junctions generally have a half-life of 2 to 5 hours (Beardslee et al.,
1998; Fallon and Goodenough, 1981) and it is thought that their rapid turnover and reassembly
allows the cell to respond quickly to disruptions in tissue homeostasis by making necessary
changes in the level of GJIC: for example, following tissue injury (Churko and Laird, 2013).

1.1.2 Connexin Gene Mutations and Human Disease
Twenty-one members exist in the connexin family and all have distinct, yet often overlapping
tissue expression profiles, suggesting they are critical to human physiology (Avshalumova et
al., 2014; van Steensel, 2004). Furthermore, connexin gene mutations have been linked to
many human pathologies including skin disorders, hearing loss, cardiopathies,
neurodegenerative diseases, bone and cartilage abnormalities, and cataracts (Garcia et al.,
2016b). Due to the complexity of the connexin life cycle, connexin mutations can affect their
!
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intracellular trafficking, hemichannel function, gap junction function, stability at the cell
membrane, or even compatibility with other connexins (Garcia et al., 2016a; Kelly et al., 2014;
Scott et al., 2012). Not surprisingly, connexin gene mutations often result in disease affecting
multiple tissues that express the specific connexin (Garcia et al., 2016b). This is exemplified
in patients harbouring GJB2 mutations that have hearing loss with the comorbidity of skin
disease due to the expression of Cx26 in both the inner ear and epidermis (Arita et al., 2006;
de Zwart-Storm et al., 2008b; Martin and van Steensel, 2015; Richard et al., 2004). In addition,
some connexin mutants produce no disease at all, likely because connexins have the ability to
compensate for others within the same subgroup (Zheng-Fischhofer et al., 2007). This
phenomenon is evident in the case of the Bart-Pumphrey Syndrome-causing N54K Cx26
mutant in the skin, which lowers Cx26 expression, but is compensated by an increased
expression of Cx30 (Richard et al., 2004). Human epidermis expresses 7 connexin proteins in
overlapping stages of keratinocyte differentiation including Cx26, Cx30, and Cx43, making
the skin an extremely complex tissue in terms of intercellular communication. (Di et al., 2001;
Martin et al., 2014). Due to the dynamic nature of this outward-facing stratified epithelium, a
high level of intercellular communication is likely required to coordinate the correct balance
of keratinocyte proliferation and differentiation.

1.1.3 Epidermal Physiology
Human and mouse epidermis (Fig. 1.1) consist of four principle strata of keratinocytes; the
stratum basale, stratum spinosum, stratum granulosum, and stratum corneum which faces the
external environment (Menon et al., 2012). Highly proliferative basal keratinocytes detach
from the underlying basement membrane and undergo a ~14-day terminal differentiation
program as they transition through the epidermal layers (Candi et al., 2005; Segre, 2006).
Keratinocytes of the stratum spinosum synthesize keratin filaments that form an extensive
cytoskeleton to provide mechanical strength to cells (Segre, 2006). Keratinocytes of the
stratum granulosum produce intracellular keratohyaline granules and lamellar bodies that
release structural proteins and ceramides which further provide cells with mechanical strength
and hydrophobicity. An important keratin filament aggregating protein, filaggrin, is released
from keratohyaline granules and condenses the keratin cytoskeleton of differentiating
keratinocytes to form flat sheet-like cells (Sandilands et al., 2009). Additionally, filaggrin is
!
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Figure 1.1. Connexin protein expression in unwounded and wounded mouse epidermis.
Adult epidermis is composed of 4 layers of keratinocytes (stratum basale, stratum spinosum,
stratum granulosum, stratum corneum) which express up to 7 distinct connexin proteins in
overlapping distribution patterns. Notably, Cx43 is expressed mostly in the stratum spinosum
and in some cells of the stratum basale, while Cx26 and Cx30 are weakly expressed in the
stratum granulosum. Twenty-four hours after an epidermal wound, Cx26 and Cx30 are
expressed in keratinocytes at the wound margins, whereas Cx31.1, Cx40, and notably, Cx43
are markedly downregulated in keratinocytes at the wound margin. Figure used with
permission from Dr. Jared Churko.
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degraded by proteases in the stratum corneum into free amino acids and derivatives which
constitute the skin’s natural moisturizing factor (Sandilands et al., 2009). Terminal
differentiation involves a specialized form of apoptosis, called cornification (Eckhart et al.,
2013), whereby keratinocytes transition into enucleate flattened cells, which amongst many
layers, weave together to form a protective external covering (Menon et al., 2012). Between
interlocked corneocytes is a mortar of hydrophobic ceramides that generates an effective
outward-in waterproof barrier (Menon et al., 2012). Together these layers give the epidermis
its structural integrity, resiliency to damage, and impermeability to water and microbes (Segre,
2006). It is important to note that the epidermis (especially the stratum corneum) varies greatly
in thickness between volar skin where it is thickest, and dorsal skin where it is considerably
thinner (Segre, 2006). Epidermal thickness may correlate with the amount of mechanical stress
endured by each anatomical region of skin.
A key factor thought to be involved in keratinocyte differentiation is an increasing calcium
(Ca2+) gradient found between cells of the stratum basale and granulosum (Bikle et al., 2012).
Approximately 2µM of Ca2+ are found in the basal layer which triple by the granular layer,
and fall to very low levels in the stratum corneum (Behne et al., 2011). Hemichannels have
been shown to release adenosine triphosphate (ATP) that can influence purinergic signaling
and intracellular Ca2+ handling in an autocrine/paracrine fashion (Baroja-Mazo et al., 2013),
which may affect the natural calcium gradient. Furthermore, GJs regularly permit the passage
of inositol-trisphosphate (IP3) (Alexander and Goldberg, 2003) which is known to affect Ca2+
mobilization, and is likely important in the establishment and maintenance of this gradient,
and therefore keratinocyte differentiation.
Cx43 has been highly characterized in many tissues including the skin due to its nearly
ubiquitous expression and implication in human diseases (Laird, 2008). Cx43 is expressed in
dermal fibroblasts as well as the keratinocytes of the stratum basale, spinosum, and
granulosum (Churko and Laird, 2013). However, approximately 10% of basal cells do not
express Cx43 and these are thought to resemble stem cells (Matic et al., 2002). Both Cx26 and
Cx30 are expressed at low levels in the stratum granulosum and minimally in the stratum
spinosum (Scott et al., 2012; Wiszniewski et al., 2000). Currently, the roles of Cx26 and Cx30
are not well understood in the skin but some studies have revealed Cx26 may influence
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keratinocyte differentiation and/or proliferation (Djalilian et al., 2006; Lucke et al., 1999;
Maher et al., 2005). However, researchers are uncovering the importance of connexins in skin
health and wound healing as 11 inheritable skin diseases are correlated with mutations in 5
distinct connexin genes (Lilly et al., 2016).

1.1.4 Cutaneous Wound Healing
In the case of injury, the skin repairs itself through a highly dynamic process in which key
events spatially and temporally overlap (Martin, 1997; Reinke and Sorg, 2012). Immediately
following an injurious breach of the skin barrier, damaged blood vessels vasoconstrict to
prevent excessive blood loss while thrombogenesis initiates the generation of a protective clot
that plugs the exposed wound (Reinke and Sorg, 2012). Along with the release of cytokines
from platelets, local blood vessels dilate to recruit immune cells to clean up debris and
opportunistic pathogens (Martin, 1997). Damaged keratinocytes, endothelial cells, and
invading immune cells secrete growth factors to initiate fibroblast proliferation and
angiogenesis which infiltrates the thrombus to generate a dense granulation tissue composed
of fibroblasts, thick collagen bundles, immune cells, and a dense capillary network (Martin,
1997). Growth factors also stimulate wound edge keratinocytes to adopt migratory behaviour
wherein they crawl along the underside of the granulation tissue, while keratinocytes behind
wound margins become highly proliferative to aid in re-epithelialization (Martin, 1997). Upon
re-epithelialization, keratinocytes differentiate to re-establish the functional epidermal layers
as cells in the granulation tissue undergo apoptosis until the entire tissue and clot are lost
(Reinke and Sorg, 2012). The time required for complete epidermal re-establishment
following wounding can vary greatly depending on the severity and type of wound, the age of
the individual, and the presence of infection (Martin, 1997). Notably, diabetics display poor
wound healing capabilities and often develop chronic non-healing wounds (Lim et al., 2015).
While this context is undoubtedly multi-factorial, some suggest that a deregulation of
epidermal connexins contributes to impaired healing in diabetics (Wang et al., 2007a). In
additional, chronic venous leg ulcers have repeatedly demonstrated chronically upregulated
Cx26, Cx30, and Cx43, suggesting that dynamic connexin regulation is necessary for proper
wound healing (Brandner et al., 2004; Ghatnekar et al., 2015; Mendoza-Naranjo et al., 2012;
Sutcliffe et al., 2015).
!
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1.1.5 Connexins Involved in Cutaneous Wound Healing
It has been found that during normal wound healing, extensive gap junction remodeling occurs
(Becker et al., 2012; Churko and Laird, 2013). Several studies have shown a dramatic decrease
in the expression of Cx43 in keratinocytes surrounding the wound site at the onset of healing
(Brandner et al., 2004; Goliger and Paul, 1995; Kretz et al., 2003; Lampe et al., 1998).
Furthermore, reducing Cx43 expression has been shown to improve keratinocyte proliferation
and migration, limit inflammation and scaring, and promote overall beneficial wound healing
outcomes (Churko et al., 2012; Ghatnekar et al., 2015; Mori et al., 2006; Qiu et al., 2003). On
the other hand, both Cx26 and Cx30, which are normally located in the stratum granulosum,
are expressed at high levels throughout all layers of the epidermis surrounding the wound site
early in healing (Coutinho et al., 2003; Davis et al., 2013; Djalilian et al., 2006; Goliger and
Paul, 1995; Kretz et al., 2003; Lemaitre et al., 2006). Down-regulation of these connexins later
in the healing process is normal and may be necessary for later stages of healing (Brandner et
al., 2004; Djalilian et al., 2006). Shortly after wounding, keratinocyte hyperproliferation
results in epidermal thickening (Martin, 1997), and since numerous gain of function Cx26 and
Cx30 mutants lead to hyperproliferative skin diseases (Xu and Nicholson, 2013), it is possible
these connexins may promote a proliferative burst to jump start wound healing. However, little
is known as to what roles Cx26 and Cx30 play in maintaining healthy epidermis. Furthermore,
although their remodeling has been demonstrated during wound healing, it is unknown
whether Cx26 and Cx30 gene mutations alter wound healing properties.

1.1.6 GJB2 Mutations Involved in Skin Disease
Cx26 is encoded by the GJB2 gene and is becoming a highly characterized member of the
connexin family. To date, well over 100 distinct GJB2 mutations have been reported in
patients with skin disease and/or hearing loss (Connexin-deafness homepage) (Laird, 2006;
Lilly et al., 2016; Xu and Nicholson, 2013). Refer to Fig. 1.2 for an extensive depiction of
these mutants on the Cx26 polypeptide. Six distinct skin diseases are specifically linked to
GJB2 mutations that present with focal, or generalized skin abnormalities and often feature
keratoderma (thickening of the epidermis) (Lilly et al., 2016). For example, KeratitisIchthyosis-Deafness Syndrome (KIDS), Bart-Pumphrey Syndrome and Vohwinkel
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Figure 1.2. Composite diagram of reported disease-linked Cx26 mutants.
The Cx26 polypeptide sequence highlighting the location of numerous disease-linked mutants.
Spanning every domain of the Cx26 protein, over 100 distinct Cx26 mutants (not all shown)
are linked to non-syndromic hearing loss (green circles) and syndromic skin disease (red
circles).
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Syndrome, stem from GJB2 mutations and are characterized as diffuse, hyperproliferative skin
diseases, whereas palmoplantar keratoderma with deafness can present with focal keratoderma
on volar skin (Avshalumova et al., 2014). A GJB2 gene mutation however, may lead to skin
disease, hearing impairments, or both, and some mutations lead to more profound disease than
others (Lee and White, 2009). For example, in KIDS alone, the G45E Cx26 mutant leads to
an infant-lethal form (Koppelhus et al., 2011), while a milder form is caused by the N14K
mutant (Lazic et al., 2008). Numerous mutants affecting the NT (amino acids, 1-20) and EL1
(amino acids 41-75) domains are known to form leaky hemichannels (G11R, G12R, N14K,
N14Y, S17F, A40V, G45E, D50A, D50N) and are linked to syndromic pathologies displaying
severe skin disease and hearing impairments (Garcia et al., 2016a). Interestingly, the S17F
Cx26 mutant has been reported to bind with Cx43, a non-traditional binding partner, and form
leaky heteromeric hemichannels (Garcia et al., 2015). The connection between leaky
hemichannels and syndromic disease suggests they may contribute to both skin disease and
hearing loss in patients. Studies have also shown that some GJB2 mutations render nonfunctional Cx26 gap junctions but do not confer any form of skin disease, likely due to
compensation from other connexins in the epidermis (Scott et al., 2012). A possible reason for
these differences among disease potential could be due to certain mutations acting in a transdominant manner by affecting other connexins. While many mutations have been identified,
it is not fully understood how and which mutant connexins interact with other connexins,
modify channel properties, and finally disrupt tissue homeostasis.

1.1.7 GJB6 Mutations Involved in Skin Disease
Cx30 is encoded by the GJB6 gene and has received less investigative attention than
Cx26 and Cx43. Currently, five mutations are linked to syndromic skin diseases (Clouston
Syndrome, KIDS, and Vohwinkel Syndrome) and two are linked to non-syndromic hearing
loss (Fig.1.3). Clouston Syndrome is a rare condition characterized by varying severities of
palmoplantar keratoderma, alopecia, and nail dystrophy (Lamartine et al., 2000) and is
prevalent among the French-Canadian population due to a founder effect (Kibar et al., 2000).
Some mutations leading to skin disease have been shown to induce cell death pathways in
vitro (V37E and A88V) (Berger et al., 2014), while others display trafficking defects (G11R
and G59R) (Essenfelder et al., 2004; Nemoto-Hasebe et al., 2009). Furthermore, G11R and
!
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Figure 1.3. Composite diagram of reported disease-linked Cx30 mutants.
The Cx30 polypeptide sequence highlighting the location of disease-linked mutants. T5M and
A40V are the only mutants linked to non-syndromic hearing loss (green circles), whereas the
5 other mutants are associated with syndromic skin diseases (red circles).
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A88V Cx30 may form leaky hemichannels that increase purinergic signaling and deregulate
keratinocyte proliferation/differentiation (Berger et al., 2014; Essenfelder et al., 2004).
Despite these observations, it is still poorly understood how Cx30 contributes to overall skin
integrity. However, relative to Cx26, the lack of Cx30 mutations linked to hearing loss and
skin disease predicts that Cx30 may have a smaller contribution to auditory and epidermal
physiology.

1.1.8 Modeling Connexin-Linked Skin Disease
While cellular based experiments are useful for understanding certain aspects of gap
junction function or malfunction, animal based models are superior for understanding the role
of connexins in the skin as a complete tissue. Numerous researchers have employed rodent
models to study connexins in the skin and also to investigated their effects on wound healing
(Bakirtzis et al., 2003; Bosen et al., 2014; Churko et al., 2011a; Djalilian et al., 2006; Schutz
et al., 2011; Wang et al., 2007a). Several of these models express connexin mutants to
genetically mirror human connexin-linked skin diseases. For example, the G60S Cx43 mouse
represents human oculodentodigital dysplasia (Churko et al., 2011a), the conditional D66H
Cx26 mouse represents true Vohwinkel Syndrome (Bakirtzis et al., 2003), the F137L Cx31
mouse represents erythrokeratoderma variabilis (Schnichels et al., 2007), and as I will discuss,
the S17F Cx26 and A88V Cx30 mice represent human KIDS, and Clouston Syndrome,
respectively (Bosen et al., 2014; Schutz et al., 2011). Additionally, numerous studies,
including previous work from our lab (Churko et al., 2012; Churko et al., 2010; Churko et al.,
2011b; Langlois et al., 2007; Maher et al., 2005), have generated a greater understanding of
the role of Cx43 in the epidermis, its effects on wound healing, and how certain mutations
impact skin health. Some researchers have repeatedly demonstrated the benefits of Cx43
inhibition during healing (Coutinho et al., 2005; Ghatnekar et al., 2015; Grek et al., 2015;
Grupcheva et al., 2012; Qiu et al., 2003) and even started companies to develop and
commercialize Cx43-targetted wound therapies (Colin Green and David Becker – CoDa
Therapeutics; Gautnam Ghatnekar – FirstString Research). There is, however, only one Cx26
mouse model that has been used to assess the influence of Cx26 on wound healing, which has
proposed a role for Cx26 during wound inflammation and epidermal remodeling (Djalilian et
al., 2006). Despite this, and the evidence suggesting Cx26 and Cx30 are dynamically regulated
!
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during proper wound healing, there remains insufficient animal models to investigate their
impact and potential therapeutic value towards wound healing.
Recently, a group from Germany lead by Klaus Willecke has generated two disease-linked
mutant mouse strains that are suitable models of human KIDS and Clouston Syndrome: the
Cx26S17F/+ mouse and Cx30A88V/+ mouse, respectively (Bosen et al., 2014; Schutz et al., 2011).
As described in this thesis, our laboratory has generated a tissue specific S17F Cx26 mouse
(Cx26K14-S17F/+) in which the mutant connexin was expressed solely in tissues expressing
keratin 14 (K14). Cre-recombinase insertion of the mutant gene only occurred in tissues
expressing K14 and resulted in selective expression of S17F Cx26 in basal cells of the
epidermis and a few other stratified epithelial tissues, while under the expression of the
endogenous Cx26 promoter. This allowed us to study the effect of the S17F Cx26 mutant on
the epidermis with presumably far less complications from its expression in other tissues such
as the liver, kidney, intestine, placenta, mammary gland, and brain (Filippov et al., 2003;
McLachlan et al., 2007). In addition, we have obtained the A88V Cx30 mutant mice
(Cx30A88V/+ and Cx30A88V/A88V) from the Willecke laboratory. Together, we will use these
mice to gain insight into the physiological and pathological mechanisms in which connexins
and connexin mutants affect epidermal homeostasis and wound healing. The importance of
using disease-relevant mouse models lies in the genetic consistency that reference cell
experiments cannot recapitulate. These mice have the correct ratio of mutant to wild-type
alleles; something that is very difficult to reliably attain in cellular transfection-based
experiments. This gives us the advantage of being able to use mutant mice to culture primary
keratinocytes for in vitro experiments, while the genetic dosage of the mutant alleles mirrors
that of the human disease. Lastly, these mice allowed us to examine the temporal and spatial
localization of mutant connexins within intact murine epidermis while establishing a platform
to perform wound healing experiments.

1.1.9 Hypothesis
We hypothesized that disease-linked Cx26 and Cx30 mutants disrupt epidermal homeostasis
and wound healing through modification of keratinocyte proliferation, differentiation, and
migration. To test this hypothesis, we expressed five Cx26 mutants (N14K, D50N, N54K,
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M163V, S183F) in reference cells and keratinocytes to evaluate their cellular characteristics.
For each mutant, we investigated their ability to traffic, form gap junction channels, plasma
membrane hemichannels, and to exhibit trans-dominant effects on Cx30 and Cx43, as well as
the ability to induce cell death. We further modeled connexin-linked skin diseases using a
tissue-specific S17F Cx26 mutant mouse, and a global A88V Cx30 mutant mouse. The foot
pad skin of these mice were assessed to investigate the effect of the mutants on keratinocyte
differentiation, proliferation, and skin morphology. Primary keratinocytes were isolated from
these mice to assess connexin localization, overall GJIC competency, and collective cell
migration. Finally, wound healing was assessed in these mice using a standard dorsal skin
punch biopsy. The goal of these investigations was to determine the effect of Cx26 and Cx30
mutants on the epidermis and wound healing, and to shed light on the role of Cx26 and Cx30
in normal healthy skin.

1.1.10 Objectives
The specific objectives for this study were to:
1. Characterize the skin phenotype in mice harbouring Cx26 and Cx30 mutants.
2. Examine the consequences of keratinocytes harbouring connexin mutants in primary
mouse cultures and cells engineered to express Cx26 mutants.
3. Assess epidermal wound closure and remodeling in response to wounding in mutant
mice and littermate controls.
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Chapter 2
Induction of cell death and gain-of-function properties of Cx26
mutants predict the severity of diseases linked to GJB2 mutations
Here we investigated five autosomal dominant Cx26 mutants (N14K, D50N, N54K, M163V,
S183F) that are linked to various syndromic or non-syndromic diseases to uncover the
molecular mechanisms underpinning their link to disease. We demonstrated that when the
N14K and D50N mutants were expressed in gap junction-deficient HeLa cells, cells were
triggered into a cell death pathway. The N54K mutant was retained primarily within
intracellular compartments and displayed trans-dominant properties on coexpressed Cx30 and
Cx43. The S183F mutant formed some gap junction plaques but was largely retained within
the cell and exhibited only a mild trans-dominant reduction in gap junctional intercellular
communication when co-expressed with Cx30. The M163V mutant which causes hearing loss
alone exhibited impaired gap junction function and showed no trans-dominant interactions.
Taken together, we suggest that Cx26 mutants that promote cell death or cause reductions in
the functions of connexins co-expressed in keratinocytes will lead to skin diseases and hearing
loss while mutants that have reduced channel function but exhibit no aberrant effects on coexpressed connexins cause only hearing loss. Moreover, GJB2 mutations that cause cell death
lead to more severe syndromic disease.
A version of this chapter will be submitted for publication by the end of the month.
Authors: Eric R. Press, John J. Kelly, Katrina Chin, Anton Alaga, Qing Shao, and Dale W.
Laird
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Introduction

The GJB2 gene encoding connexin26 (Cx26) has an estimated mutation prevalence of 3% in
the general population (Chan and Chang, 2014). Globally, an estimated 17.3% of hearing loss
cases are linked to bi-allelic GJB2 mutations highlighting the importance of Cx26 in hearing
(Chan and Chang, 2014). In addition, numerous syndromic diseases exhibiting hearing deficits
and a variety of skin abnormalities are linked to GJB2 missense mutations with autosomal
dominant inheritance (Avshalumova et al., 2014). Interestingly, some speculate the
pervasiveness of GJB2 mutations may result from a selective heterozygote advantage (Chan
and Chang, 2014) conferred by sub-clinical epidermal thickening and a stronger cutaneous
barrier (D'Adamo et al., 2009). In humans, Cx26 is expressed in a variety of tissues and not
surprisingly, in several cell types within the cochlea (Jagger and Forge, 2015) and in
keratinocytes of the epidermis (Scott et al., 2012). Within these tissues, several other members
of the connexin family are expressed, most notably Cx30 and Cx43, wherein mutations in their
genes have also been implicated in syndromic diseases sharing some similar features
(Avshalumova et al., 2014; Martin et al., 2014; Scott et al., 2012).
Cx26 is a gap junction protein that oligomerizes in the cell to form hexameric transmembrane
channels called connexons (Laird, 2006). Connexons that span the plasma membrane are
called hemichannels and may allow a cell to pass small signalling molecules between the
cytosol and the extracellular environment (Laird, 2006). However, when hemichannels from
adjacent cells dock together, they form a single conduit called a gap junction channel which
connects the cytosol of these cells and facilitates gap junctional intercellular communication
(GJIC) (Laird, 2006). ATP, IP3, and cations frequently pass through Cx26 gap junction
channels and have been shown to play important roles in regulating cell proliferation and
differentiation as well as maintaining ionic homeostasis within tissues. (Alexander and
Goldberg, 2003; Djalilian et al., 2006).
The Cx26 polypeptide chain has four transmembrane domains, two extracellular loops, an
intracellular loop, and cytosolic N- and C- termini. The N-terminal domain (amino acid
residues 1-20) is suggested to play a major role in voltage sensing and channel gating (Maeda
et al., 2009). The extracellular loops (E1 and E2) (amino acid residues 41-75 and 155-192,
respectively) are thought to be key domains for oligomerization and inter-channel docking
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(Maeda et al., 2009). Disease-causing point mutations have been documented to affect every
domain of the Cx26 polypeptide, and depending on the mutation and the motif that harbors
the altered residue, variations can occur in connexin folding and trafficking, channel assembly,
channel gating, half-life, degradation, and/or interactions between other co-expressed
connexins (Laird, 2006). Some mutants have been shown to disrupt several connexin lifecycle characteristics (Garcia et al., 2015) increasing the complexity of delineating how GJB2
gene mutations can cause diseases that affect one or more organs and vary in severity.
In this study we selected 5 autosomal dominant GJB2 missense mutations that result in single
amino acid substitutions in various domains of the Cx26 polypeptide and are linked to an array
of auditory and skin pathologies. The N14K mutant causes a disease that shares symptoms
with Clouston Syndrome and KIDS (Lazic et al., 2008), the D50N mutant leads to KIDS
(Mazereeuw-Hautier et al., 2007), the N54K mutant results in Bart-Pumphrey syndrome
(Richard et al., 2004), and the S183F mutant causes palmoplantar keratoderma and hearing
loss (de Zwart-Storm et al., 2008b). Finally, the M163V mutant is linked to moderate hearing
loss only (Marlin et al., 2001). Considering the pleiotropic nature of the Cx26 mutants, we
proposed that mutants which give rise to similar clinical presentations would share common
mechanisms of action.
Here we found that the N14K and D50N mutants leading to wide spread erythrokeratoderma
and severe hearing loss caused cell death, the N54K and S183F mutants leading to
palmoplantar keratoderma and hearing loss had trafficking defects and reduced channel
function, and the M183V mutant leading to hearing loss alone had reduced channel function.
Lastly, all mutants linked to syndromic disease had trans-dominant effects on co-expressed
connexins.

2.2

Materials and Methods

2.2.1 Cell Culture
Connexin-deficient cervical cancer cells (HeLa) as described in (Elfgang et al., 1995) were
purchased from ATCC and Rat Epidermal Keratinocytes (REKs) originally characterized in
(Baden and Kubilus, 1983) were generously provided by Dr. Vincent Hascall. All cells were
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grown in DMEM (Life Technologies Cat# 11965-092) supplemented with fetal bovine serum,
2 mM L-glutamine (Life Technologies Cat# 25030-081), penicillin and streptomycin
according to (Penuela et al., 2007).

2.2.2 cDNA Constructs and Transfections
cDNA encoding human Cx26 was provided by Dr. C. G. Naus (University of British
Columbia, Vancouver, BC, Canada). PCR was used to add XhoI and EcoRI restriction sites
to the 5′ and 3′ ends of Cx26 and the resulting cDNAs were cloned into the pEGFP-N1 vector
(BD Biosciences Clontech) and sequenced for verification with a 17-amino-acid linker
sequence separating the Cx26 and GFP moieties. Constructs encoding human N14K, D50N,
N54K, M163V, and S183F Cx26-GFP were further obtained from NorClone by using a
QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) in accordance with the
manufacturer's instructions. RFP-tagged Cx30 and Cx26 constructs were previously described
(Berger et al., 2014). All constructs were validated by sequencing. GFP and RFP tags were
shown not to dramatically affect connexin trafficking or protein function as previously shown
(Thomas et al., 2005). Cells at ~60% confluency in 35 mm dishes were transiently transfected
using Lipofectamine 2000. Transfection mixtures contained 200 µl of Opti-MEM Reduced
Serum Medium (Life Technologies Cat# 31985-070), 1 µl of LF2000 transfection reagent
(Invitrogen Cat# 11668019), and 1 µg of GFP-tagged Cx26, N14K, D50N, N54K, M163V, or
S183F cDNA constructs. For co-expression experiments, transfection mixtures differed in that
0.5 µg of GFP-tagged constructs plus 0.5 µg of RFP-tagged Cx26 or Cx30 were added to
produce roughly equal expression of mutant to WT connexins. The mixture was gently
swirled, incubated at room temperature for 10 minutes, and added drop-wise to cells growing
in DMEM. All cells were used for experiments between 24-48 hours following transfection.

2.2.3 Immunofluorescent labeling
HeLa cells or REKs grown to ~80% confluency on sterile glass coverslips, were washed with
phosphate-buffered saline (PBS), and fixed in an ice-cold solution of 80% methanol and 20%
acetone for 10 minutes. Coverslips were then washed in PBS, blocked in a 2% bovine serum
albumin (BSA) solution (diluted in PBS) for 30 minutes then incubated at room temperature
for 1 hour with the following primary antibodies diluted in BSA solution: 1/500 mouse antiprotein disulfide isomerase (PDI) (Assay Designs Cat# SPA-891) or 1/500 rabbit anti-Cx43
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(Sigma-Aldrich Cat# C6219) or 1/200 rabbit anti-cleaved caspase 3 (Sigma-Aldrich Cat#
C8487). Secondary antibodies 1/500 Alexa-488-conjugated anti-mouse (Invitrogen: Cat#
A11017) and 1/500 Alexa-555-conjugated anti-rabbit (Invitrogen Cat#A21429) were used to
detect primary antibodies. Cells were then incubated for 10 minutes at room temperature with
Hoechst 33342 (1/1000 diluted in ddH20) (Molecular Probes Cat# H3570), mounted with
Airvol (containing 15% polyvinyl alcohol, 33% glycerin, and 0.1% sodium azide), and imaged
with a Zeiss LSM 800 confocal Airyscan microscope equipped with ZenWorks software.
Images were captured with a 63x oil immersion objective. Gap junction plaques between
REKs were quantified in a blinded fashion by counting the number of green and red punctae
at individual cell-cell interfaces. A minimum of 24 separate images were captured for each
mutant and a one-way ANOVA was performed on the means of 3 biological replicates.

2.2.4 Dye Transfer Studies
HeLa cells or REKs grown to ~60% confluency and engineered to express GFP-tagged Cx26
or Cx26 mutants (and RFP-tagged connexins for co-expression experiments) as described
above were microinjected with Alexa-Fluor-350 (410 Da, Molecular Probes Cat# A10439) to
assess gap junction dye transfer previously described (Huang et al., 2013). Briefly, cells were
microinjected using a fine glass needle attached to an Eppendorf FemtoJet automated
microinjector. Cells were imaged using a Leica DM IRE2 epifluorescent microscope to
visualize GFP and RFP, then one minute following microinjection, they were imaged again to
visualize the spread of Alexa-Flor-350. All images were captured with a 20x objective. The
incidence of dye transfer within each trial was quantified as the percent of microinjected cells
that passed dye to neighbouring cells and a one-way ANOVA was performed on the means of
at least 3 replicates. Tukey’s post-hoc test compared the means of each condition to the
condition in which cells expressed GFP-tagged WT Cx26. Untransfected HeLa cells were used
as negative controls and HeLa cells expressing Cx26-GFP only, or in addition to Cx26-RFP
or Cx30-RFP served as positive controls for all dye transfer experiments in HeLa cells. Lastly,
for dye transfer experiments in REKs, untransfected REKs, or REKs expressing Cx26-GFP
were used as positive controls.

2.2.5 Hemichannel Assay
HeLa cells were seeded at low density to isolate cells from one another and then were
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engineered to express Cx26 or Cx26 mutants as described above. Propidium iodide (PI) dye
uptake assays to assess hemichannel activity were performed as noted in (Berger et al., 2014).
Briefly, cells were washed in extracellular solution (ECS) (142 mM NaCl, 5.4 mM KCl, 1.4
mM MgCl2, 2 mM CaCl2, 10 mM HEPES, 25 mM D-glucose, osmolarity 298 mOsm, pH
adjusted to 7.35 using NaOH) and then twice in either ECS or divalent cation free solution
(DCF-ECS) (same as ECS but with Ca2+ and Mg2+ substituted for 2 mM EGTA). ECS or DCFECS containing 1 mg/ml PI (668.4 Da, Invitrogen) was added to the cells and incubated at
37˚C for 15 minutes. Cells were washed 3 times with ECS, then ~40 isolated cells per replicate
were imaged to visualize GFP and PI using the Leica microscope and OpenLab software. For
each replicate, the number of cells containing PI was recorded as a percentage of the total
number of GFP-positive cells and a two-way ANOVA was performed on the means of at least
3 replicates. Sidak’s post-hoc test compared the means of ECS and DCF-ECF conditions.

2.2.6 Statistical Analysis
Graph Pad Prism version 6 was used for all statistical analysis and statistical significance was
noted when p<0.05. All histogram values represent the mean + SEM.

2.3

Results

2.3.1 N14K and D50N mutants induce cell death in vitro
In order to assess the impact of Cx26 mutants on cellular health, specific Cx26 mutants were
expressed in GJIC-deficient HeLa cells. HeLa cells expressing the N14K and D50N mutants
displayed pyknotic nuclei and blebbing as early as 24 hours post transfection, therefore we
immunolabelled cleaved caspase 3 (CC3) to determine if cells expressing these mutants were
undergoing apoptosis (Fig 2.1A). HeLa cells expressing the GFP-tagged N14K and D50N
mutants displayed a high degree of CC3 immunolabeling (Fig. 2.1B), similar to cells treated
with staurosporine, suggesting that the expression of these mutants in HeLa cells triggers
apoptosis in vitro. Consequently, cell expressing the N14K or D50N mutants were deemed
not suitable for further mutant localization or functional studies.
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Fig. 2.1. N14K and D50N Cx26 mutants linked to KIDS induce cell death. (A) HeLa cells
expressing GFP-tagged Cx26, N14K, and D50N mutants (green) were immunolabelled to
highlight cleaved-caspase-3 (red) indicating cells undergoing apoptosis and nuclei were
stained with Hoechst (blue). Cells treated for 2 hours with 1µM staurosporine were used as a
positive control for apoptotic cells. (B) Cells expressing N14K and D50N mutants were often
apoptotic compared to Cx26 expressing cells ****p<0.0001, N=3 separate experiments. Scale
bar = 40µm.
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2.3.2 N54K and S183F mutants have trafficking defects and impaired dyetransfer ability
Cx26 mutants associated with hearing loss and various skin diseases were expressed in HeLa
cells to examine how a substituted amino acid in Cx26 may affect its trafficking, cellular
localization, or gap junction function. Cx26 and the M163V mutant formed abundant gap
junction plaques at cell-cell interfaces (Fig. 2.2A). The S183F mutant was retained primarily
in intracellular compartments but formed a small number of gap junction plaques while the
N54K mutant colocalized extensively with PDI labelling of the endoplasmic reticulum (ER)
(Fig. 2.2A). The ability of the disease-linked mutants to form functional gap junction channels
was assessed by quantifying intercellular transfer of microinjected Alexa-Fluor-350 in HeLa
cells expressing Cx26 or the various mutants. Paired cells expressing Cx26 had nearly 100%
incidence of dye transfer (Fig. 2.2B) while cells expressing the M163V mutant passed dye
approximately 40% of the time. Cells expressing either the N54K or S183F mutants were
essentially unable to establishing gap junction channels capable of dye transfer similar to
controls (Fig. 2.2B).

2.3.3 Cx26 mutants exhibit dominant-negative effects on Cx26 function.
To assess the distribution and function of Cx26 mutants under physiological conditions where
both wild type and mutant Cx26 are expressed in the same cell, we engineered HeLa cells to
express RFP-tagged Cx26 and GFP-tagged Cx26 mutants at approximately a 1:1 ratio. Cx26
and the M163V mutant formed numerous gap junction plaques at the cell surface and were
highly colocalized (Fig. 2.3A). Surprisingly, the N54K mutant was able to traffic to the cell
surface and form intermixed gap junction plaques when co-expressed with Cx26 (Fig. 2.3A).
The S183F mutant remained distributed in intracellular compartments, however was also
found in several plaques when co-expressed with Cx26 (Fig. 2.3A). These findings suggest
that all mutants were more readily assembled into a gap junction plaque when co-expressed
with Cx26. To further examine the interaction between the Cx26 mutants and wild-type Cx26,
we quantified Alexa-Fluor-350 dye-transfer between HeLa cells that coexpressed the mutants
and Cx26 (Fig 2.3B). Cells expressing M163V and S183F mutants reduced the overall
functional gap junctional status of Cx26. However, the N54K mutant abolished the functional
gap junctional status of co-expressed Cx26 as assessed by the ability to pass a fluorescent dye.
(Fig 2.3B).
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Fig. 2.2. Cx26 mutants linked to skin disease are frequently localized to intracellular
compartments and have limited dye transfer capability. (A) HeLa cells expressing GFPtagged Cx26, N54K, M163V, or S183F mutants (green) were immunolabeled for protein
disulfide isomerase (PDI, red), a resident protein of the endoplasmic reticulum, and stained
with Hoechst (blue) to denote the nuclei. Cx26 and the M163V mutant form numerous gap
junction plaques at cell interfaces (arrows). N54K and S183F mutants were mostly located
within the cell while the S183F mutant formed a few gap junction plaques. (B) Alexa-Fluor350 dye transfer in pairs or clusters of HeLa cells expressing N54K and S183F mutants was
negligible whereas ~ 40% of the cells expressing the M163V mutant transferred dye (C).
Example images of dye-transfer experiments showing successful (Cx26) and unsuccessful
dye-transfer (N54K). **p<0.01, ****p<0.0001, N = 3 separate experiments. The number of
cells that were microinjected to test for dye transfer in each case is noted in (B). Ctrl represents
untransfected HeLa cells. Scale bar in (A, C) = 20µm.
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Fig. 2.3. Cx26 mutants exhibit dominant-negative properties on Cx26 in HeLa cells. (A)
HeLa cells expressing GFP-tagged Cx26 or N54K, M163V, and S183F mutants (green)
together with Cx26-RFP (red) were stained with Hoechst (blue). All mutants formed gap
junction plaques at cell interfaces (arrows) and colocalized with Cx26-RFP. (B) Untransfected
control cells (Ctrl), or cells expressing the N54K mutant together with Cx26 failed to pass
microinjected Alexa-350 dye. Cells expressing S183F and M163F mutants together with
Cx26-RFP had reduced incidences of dye transfer compared to cells expressing Cx26-GFP.
****p<0.0001, N = 3 separate experiments. The number of cells that were microinjected is
noted in (B). Scale bar = 20µm.
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2.3.4 N54K and S183F mutants display trans-dominant effects on Cx30
Since Cx26 and Cx30 are co-expressed in the same keratinocytes as well as several cell types
of the inner ear (Jagger and Forge, 2015), we engineered HeLa cells to express RFP-tagged
Cx30 and GFP-tagged Cx26 mutants to assess potential trans-dominant interactions. Cx26 as
well as the M163V and S183F mutants were able to form gap junction plaques at the cell
surface and often colocalized with Cx30 (Fig. 2.4A). The N54K mutant formed very few
plaques and remained in an ER-like distribution pattern but also appeared to impair the ability
of Cx30 to form abundant gap junction plaques indicating a trans-dominant effect on Cx30
trafficking (Fig. 2.4A). Next we determined if the Cx26 mutants exhibited a trans-dominant
effects on Cx30 channel function using Alexa-Fluor-350 dye-transfer studies (Fig. 2.4B).
Microinjected HeLa cells expressing Cx30 alone, or co-expressing Cx30 and Cx26 had nearly
100% incidence of dye-transfer. However, cells coexpressing Cx30 and either the N54K or
S183F mutants had significantly reduced ability to pass dye indicating that these mutants had
a trans-dominant effect on Cx30 channel function. Interestingly, the M163V mutant did not
significantly reduce the ability of Cx30 positive cells to pass dye.

2.3.5 N54K displays mild trans-dominant effect on endogenous Cx43
To assess the impact of Cx26 mutants in a more tissue-relevant cell, we engineered REKs to
express Cx26 mutants and determined their potential for trans-dominant effects on
endogenous Cx43. The N54K mutant formed fewer gap junction plaques than Cx26 and
remained mostly intracellular (Fig. 2.5A, B). The M163V and S183F mutants formed
numerous gap junction plaques although the S183F mutant was found in a typical ER-like
distribution pattern (Fig. 2.5A). None of the Cx26 mutants appeared to impair Cx43 gap
junction plaque formation (Fig. 2.5B). REKs engineered to express Cx26 mutants were
microinjected with Alex-Fluor-350 which readily passes through both Cx26 and Cx43 gap
junction channels. Only cells expressing the N54K mutant exhibited a significant decrease in
dye transfer suggesting that the N54K mutant had a modest trans-dominant-negative effect on
endogenous Cx43. (Fig. 2.5C).
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Fig. 2.4. Cx26 mutants linked to syndromic disease exhibit trans-dominant properties on
Cx30 in HeLa cells. (A) HeLa cells expressing GFP-tagged Cx26, N54K, M163V, and S183F
mutants (green) and RFP-tagged Cx30 (red) were stained with Hoechst (blue). S183F and
M163V mutants formed abundant gap junction plaques at cell interfaces (arrows) and
colocalized with Cx30, while S183F mutants were also located within the cell. N54K mutants
remained mostly within the cell although they formed a few gap junction plaques (arrows) and
impaired the ability of Cx30 to assemble gap junctions at the cell surface. (B) Cells expressing
the M163V mutant together with Cx30 had dye transfer abilities similar to cells expressing
Cx26 and Cx30, or Cx30 alone, whereas the incidences of dye transfer in cells expressing the
N54K and S183F mutants together with Cx30 was markedly reduced. ****p<0.0001, N ≥ 3
separate experiments. The number of cells that were microinjected in each situation is noted
in (B). Scale bar = 20µm.
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Fig. 2.5. The N54K mutant exhibits trans-dominant inhibition of endogenous Cx43 in
REKs. (A) REKs expressing GFP-tagged Cx26, N54K, M163V, and S183F mutants (green)
with endogenous Cx43 immunolabelled in red were stained with Hoechst (blue). The N54K
and S183F mutants were inefficient at forming gap junction plaques and were often found
intracellular. The M163V mutant formed abundant GJ plaques similar to Cx26. (B) The N54K
mutant formed fewer gap junction plaques compared to Cx26, however endogenous Cx43 gap
junction formation was not impaired by any of the mutants. (C) REKs expressing the N54K
mutant had reduced dye transfer capabilities compared to untransfected REKs (Ctrl), and
REKs expressing Cx26. **p>0.01, n ≥ 24 individual images. The number of cells
microinjected is noted in (C). Scale bar = 20µm.
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2.3.6 N54K and S183F mutants display reduced hemichannel function
Aside from GJIC and trafficking defects, mutant connexins may further disrupt hemichannel
properties. We therefore used a propidium iodide (PI) dye uptake assay to assess the function
of mutant hemichannels in normal extracellular solution (ECS) and divalent-cation-free ECS
(DCF-ECS) which stimulates hemichannels to open (Fasciani et al., 2013). All mutant
expressing cells displayed minimal PI uptake in ECS conditions, and similar to Cx26, the
M163V mutant exhibited nearly 100% incidence of PI uptake in DCF-ECS, indicating fully
functional hemichannel activity (Fig. 2.6B). Interestingly, in DCF-ECS, cells expressing the
N54K mutant demonstrated approximately 60% incidence of PI uptake suggesting moderately
functional hemichannel formation, while cells expressing the S183F mutant displayed no
increase in PI uptake, indicating non-functional hemichannel formation (Fig. 2.6B).

2.4

Discussion

Due to a high carrier frequency of GJB2 mutations in the population and greater than 100
disease causing Cx26 mutants now identified in humans (Lee and White, 2009; Martin and
van Steensel, 2015; Xu and Nicholson, 2013), understanding how distinct GJB2 mutations
cause disease is critical when considering any prospective therapies. The scope of possible
Cx26 dysfunction is vast considering the possibility of gain- or loss-of functions of gap
junctions, hemichannels, or additions to the connexin interactome that may present anywhere
throughout the Cx26 life-cycle. Furthermore, the complexity of Cx26 dysfunction is
compounded by its potential to interact with several co-expressed connexin binding partners
in numerous different tissues including the skin and inner ear. The pleiotropic nature of Cx26linked diseases raises obvious questions as to how specific GJB2 gene mutations lead to
hearing loss, or hearing loss combined with skin disorders of varying severity. Here we studied
five autosomal dominant Cx26 mutants: four that cause hearing loss in addition to various skin
disorders (N14K, D50N, N54K, S183F), and one that causes hearing loss alone (M163V). We
found that the N14K and D50N mutants which cause wide spread and severe skin lesions
overtly induced cell death, whereas the N54K and S183F mutants which cause regional and
moderate skin lesions, had defects in connexin trafficking, as well as impaired gap junction
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Fig. 2.6. Cx26 mutants linked to syndromic disease display reduced hemichannel
function in HeLa cells. (A) Isolated HeLa cells that were engineered to express GFP-tagged
Cx26, N54K, S183F, or M163V mutants were incubated in PI-containing ECS or DCF-ECS
and the incidence of PI-uptake was quantified from random image fields. Image fields
captured GFP-tagged connexins (green) and intracellular PI-uptake (red). (B) In DCF-ECS,
cells expressing the N54K mutant displayed approximately 60% incidence of PI-uptake and
cells expressing the S183F mutant displayed minimal PI-uptake. Cells expressing the M183V
mutant, much like Cx26, exhibited nearly 100% incidence of PI-uptake. All mutants, except
for S183F, demonstrated increased PI-uptake in DCF-ECS compared to control ECS
conditions. ****p>0.0001, N=3 separate experiments. The number of image fields is noted
below the histogram in (B). Scale bar = 50µm.
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and hemichannel function (Fig. 2.7). In addition, the M163V mutant which causes moderate
hearing loss alone, displayed only impaired gap junction function (Fig. 2.7) with no transdominant properties on other co-expressed members of the connexin family. We also showed
that while all mutants displayed dominant-negative properties on wild type Cx26, the
syndromic N54K and S183F mutants trans-dominantly impaired the function of co-expressed
Cx30 and/or Cx43 gap junctions (Fig. 2.7).
Several extensive reviews have discussed the functional characteristics of over 60 distinct
disease-causing Cx26 mutants that were investigated using heterologous expression models
(Garcia et al., 2015; Lee et al., 2009; Xu and Nicholson, 2013). These reports have elucidated
some major characteristics of disease causing mutants: a reduction or ablation of gap junction
formation/function, altered selectivity of signaling molecules, and aberrant hemichannel
activity. While syndromic and non-syndromic mutations affect amino acid residues in
cytoplasmic, extracellular, and transmembrane domains, the majority of syndromic mutations
cluster to the N-terminal and EL1 domains (Garcia et al., 2016b; Lee and White, 2009; Martin
and van Steensel, 2015; Xu and Nicholson, 2013). Additionally, it seems that mutants which
alter molecular selectivity lead only to non-syndromic hearing loss whereas aberrant
hemichannels are almost exclusively associated with severe syndromic disease (Garcia et al.,
2016b; Xu and Nicholson, 2013). Recently, the S17F mutant which leads to a relatively severe
form of KIDS, has been shown to form essentially non-functional homomeric gap junctions
or hemichannels, yet oddly produces hyperactive heteromeric hemichannels with Cx43
(Garcia et al., 2015). This finding further established that aberrant hemichannels are a common
characteristic of KIDS mutants, but importantly, it demonstrated the need to carefully examine
mutants for trans-dominant effects on co-expressed connexins – including non-traditional
binding partners. It is important to note that a trans-dominant interaction with a non-traditional
binding partner such as Cx43, can be considered a gain-of-function property. Therefore, we
also explored possible trans-dominant effects on Cx30 which is co-expressed with Cx26 in the
skin and cochlea, as well as Cx43, which is co-expressed with Cx26 in the skin and also found
in the cochlea. Furthermore, at least eight additional mutants have been identified in patients
that still require functional analysis (Martin and van Steensel, 2015). This report describes the
M163V and S183F mutants which have been limitedly investigated (Bruzzone et al., 2003;
Shuja et al., 2016), and the N54K mutant which was merely reported once in a patient with
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Mutant

Cx26

Overt Clinical Features

N14K

•
•
•
•

Mucocutaneous lesions
Patchy erythrokeratoderma
Palmoplantar keratoderma
Severe hearing loss

D50N

•
•
•

Diffuse/Patchy erythrokeratoderma
Palmoplantar keratoderma
Severe hearing loss

N54K

•
•
•

Punctate palmoplantar keratoderma
Knuckle pads + leukonychia
Severe hearing loss

M163V

•

Moderate hearing loss

S183F

•
•

Palmoplantar keratoderma
Moderate hearing loss

N14K
D50N

N54K

M163V

D50N
S183F

N14K
NH2

N54K

N54K
+ Cx30
N54K
+ Cx30

COOH
Cytosol

N54K + Cx26

N54K + Cx43

S183F

S183F + Cx26

M163V

M163V + Cx26

S183F + Cx30

S183F + Cx43

M163V + Cx30

M163V + Cx43
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Fig. 2.7. Modelling the cellular characteristics of autosomal dominant GJB2 mutations.
Table of the 5 Cx26 mutants and their associated clinical features (top left). Schematic of the
Cx26 polypeptide chain including the approximate location of each mutant included in the
study (top right). Every subsequent square displays the localization (intracellular and/or
membrane trafficking), channel formation and gap junction and hemichannel function (highly
functional = double arrows, reduced function = wavy arrows, non-functional = no entry
symbol) of each Cx26 mutant (green), and is separated into quadrants corresponding to the
context of cells co-expressing the mutant with Cx26 (blue), Cx30 (purple), or Cx43 (red).
Mutants linked to severe syndromic disease are watermarked in red, mutants linked to
moderate syndromic disease are watermarked in yellow, and mutants linked to non-syndromic
hearing loss are watermarked in green.
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Bart-Pumphrey Syndrome (Richard et al., 2004) and remains otherwise unexamined. N14K
and D50N mutants are linked to KIDS which is one of the most severe Cx26-linked skin
disorders. Patients present with erythrokeratoderma, PPK, and frequent cutaneous infections
can lead to fatal septicemia early in life (Coggshall et al., 2013). We found these mutants
strongly induced cell death such that meaningful channel function information was
unattainable. However, reports suggest they form “leaky” hemichannels when expressed in
Xenopus oocytes where they induce blebbing and substantially reduce cell viability (Lee et al.,
2009; Sanchez et al., 2016; Sanchez et al., 2013). Cx26 hemichannels are sensitive to
hyperpolarization by extracellular Ca2+ such that they remain closed under physiological
conditions (Fasciani et al., 2013). However, reduced Ca2+ sensitivity by N14K, D50N, and
several other KIDS mutants promotes hemichannel opening that can diminish transmembrane
ion gradients and release molecules including ATP that affect cell viability (Sanchez and
Verselis, 2014). Excessive ATP release is also known to stimulate purinergic signaling
capable of mobilizing intracellular Ca2+, and releasing pro-inflammatory cytokines (Burnstock
et al., 2012). In the epidermis, these mutants may also be able to disrupt the normal epidermal
Ca2+ gradient and lipid processing (Bosen et al., 2015), which can result in barrier defects and
a compensatory hyperproliferative response that drives hyperkeratosis in KIDS (Garcia et al.,
2016a). Interestingly, N14 and D50 are pore-lining residues (Garcia et al., 2016a) suggesting
that changes to the structure of the Cx26 channel pore can produce the aberrant hemichannel
properties that stand at the forefront of KIDS skin pathogenesis.
The N54K is linked to moderately severe Bart-Pumphrey Syndrome featuring PPK, knucklepads, leukonychia, and deafness, meanwhile the S183F mutant is linked to PPK with deafness.
Although no well-defined pathogenic mechanisms for PPK have been established, our
findings suggest that the high intracellular retention of N54K and S183F mutants is a common
characteristic of Cx26 mutants linked to PPK. Indeed, this trafficking defect has been indicated
in previous reports (de Zwart-Storm et al., 2008a; Martin and van Steensel, 2015; Marziano et
al., 2003; Thomas et al., 2005). The patient with Bart-Pumphrey Syndrome harbouring the
N54K Cx26 mutant in (Richard et al., 2004) was reported to have a compensatory increase in
epidermal Cx30 expression. N54 is an invariably conserved residue in the connexin family
among numerous species (Richard et al., 2004) and forms hydrogen bonds with L56 from the
opposing hemichannel (Maeda et al., 2009). Interestingly, we found that the N54K mutant
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impaired Cx30 trafficking and dye transfer, suggesting that Cx30 compensation may act to
overcome a trans-dominant hindrance of Cx26:Cx30 heteromeric gap junction formation
between keratinocytes. This study, and only a handful of others (Common et al., 2003; Di et
al., 2005; Donnelly et al., 2012; Man et al., 2007; Mhaske et al., 2013) investigated Cx26
mutants in a relevant keratinocyte model rather than connexin-deficient reference cells. We
found that only REKs expressing the N54K mutant had reduced dye transfer. This suggests
that N54K Cx26 may also exert trans-dominant effects on endogenous Cx43 which may be an
important etiological factor in Bart-Pumphrey Syndrome skin. Recently, Shuja and colleagues
demonstrated that S183F Cx26 does not form gap junctions or hemichannels in Xenopus
oocytes and junctional conductance was reduced in cells co-expressing Cx43 (Shuja et al.,
2016). We also found that the S183F mutant inhibited dye transfer in cells co-expressing Cx30,
pointing towards trans-dominant interactions of co-expressed connexins as a mechanism of
disease. Since S183 is a highly conserved residue in the connexin family among many species
(de Zwart-Storm et al., 2008b), we suggest that the S183 residue may have an indirect role in
inter-protomer binding. Additionally, moderately leaky heteromeric hemichannels formed by
S183F Cx26 and Cx43 (Shuja et al., 2016), similar to those composed of S17F Cx26 and Cx43,
may also contribute to PPK. Nevertheless, our findings provide additional evidence for the
impact of trans-dominant interactions between connexins in skin disease where disease
severity may be linked to the extent of trans-dominant influence – particularly in skin regions
exposed to greater mechanical stress.
In this study, only the M163V mutant is linked to hearing loss without added skin disease.
Since Cx26 is proposed to play an important role in potassium recycling in the inner ear
(Jagger and Forge, 2015) and dozens of hearing loss Cx26 mutants display reduced or no gap
junction function (Xu and Nicholson, 2013), it is not surprising that we found the M163V
mutant had a dominant negative effect on Cx26. However, Cx30 is also highly expressed with
Cx26 in the inner ear (Jagger and Forge, 2015) such that compensation might be able to rescue
hearing. However, several studies have shown that Cx30 cannot functionally compensate for
Cx26 in the inner ear (Cohen-Salmon et al., 2002; Qu et al., 2012; Teubner et al., 2003). This
may explain why the M163V mutant leads to hearing loss despite that HeLa cells coexpressing the M163V mutant and Cx30 passed dye at levels not unlike HeLa cells expressing
Cx30 or Cx30 co-expressed with Cx26. Including our findings from syndromic mutants, we
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suggest that mutants with trafficking defects, trans-dominant properties, and that induce cell
death lead to skin phenotypes, whereas mutants with reduced gap junction function, but do not
interfere with other co-expressed connexins produce non-syndromic hearing loss.
Human epidermis expresses 7 different connexins in overlapping populations of keratinocytes
(Di et al., 2001; Martin et al., 2014) making the epidermis a more robust system compared to
the cochlea. Fortunately, this high degree of redundant intercellular communication affords
the epidermis with resiliency in response to GJB2 mutations that have minor effects on protein
function. Because fewer connexin types are expressed within the cochlea and compensation
may be limited, small perturbations in connexin function are capable of disrupting normal
hearing. This may speak to the reason why GJB2 mutations almost never produce skin disease
alone yet Cx26-linked syndromic and non-syndromic deafness is ordinary. While the majority
of autosomal dominant GJB2 mutations produce hearing loss in addition to skin disease, we
posit that strongest predictors of syndromic disease severity actually stem from the transdominant status and gain-of-function properties of Cx26 mutant gap junctions and
hemichannels. Finally, this study provides evidence in support of genetic screening when
faced with complex syndromic diseases.
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Chapter 3
Mice harboring disease-linked Cx26 and Cx30 mutants
display volar skin abnormalities but retain most wound
healing properties.
Here we generated a novel, viable, and fertile mouse (Cx26K14-S17F/+) which expresses the
keratitis-ichthyosis-deafness syndrome (KIDS) mutant (S17F Cx26) driven from the keratin
14 promoter. This mutant mouse mirrors several Cx26-linked human skin pathologies
suggesting that the etiology of Cx26-linked skin disease indeed stems from epidermal
expression of the Cx26 mutant. Cx26K14-S17F/+ foot pad epidermis formed severe palmoplantar
keratoderma which expressed elevated levels of Cx26 and filaggrin. Primary keratinocytes
isolated from Cx26K14-S17F/+ neonates had reduced GJIC and migration. Furthermore, Cx26K14S17F/+

mouse skin healed normally after wounding but exhibited abnormal epidermal

remodeling. Mice harbouring the Clouston Syndrome A88V Cx30 mutant (Cx30A88V/+,
Cx30A88V/A88V) showed no skin abnormalities or wound healing defects suggesting that
compared to humans, Cx30 may have a less critical role in mouse epidermis. Taken together,
we suggest that Cx26 helps regulate keratinocyte differentiation, especially in palmoplantar
skin, but mice harbouring Cx26 and Cx30 mutants retain most skin wound healing properties.

A version of this chapter will be submitted for publication before the end of the year.
Authors: Eric R. Press, Katanya C. Alaga, Kevin Barr, Qing Shao, Felicitas Bosen, Klaus
Willecke and Dale W. Laird
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Introduction

Gap junction channels allow for direct intercellular communication by facilitating the passage
of small molecular messengers between the cytosol of adjacent cells (Alexander and Goldberg,
2003). Individual cells may also exchange signaling molecules with the extracellular
environment through hemichannels at the cell membrane (Saez et al., 2005). Gap junction
channels are composed of docked hemichannels from adjacent cells, each of which contains
six oligomerized connexin (Cx) subunits. Connexins comprise a family of transmembrane
proteins that have large clinical significance due to the discovery of abundant disease-causing
mutations in connexin genes. Notably, mutations in the genes encoding Cx26 and Cx30 cause
syndromic diseases where patients suffer from hearing loss and a broad range of skin
abnormalities that vary in localization and severity (Avshalumova et al., 2014; Martin and van
Steensel, 2015; Scott et al., 2012). Interestingly, Cx26 and Cx30 mutants can give rise to
diseases affecting one or multiple tissues and mutants with similar functional characteristics
often lead to similar phenotypes, suggesting specific functional anomalies are closely tied to
disease outcomes (Martin and van Steensel, 2015; Xu and Nicholson, 2013). Not surprisingly
however, Cx26 and Cx30 are both expressed in the cochlea and epidermis, and they share a
similar localization pattern within the epidermal strata (Yum et al., 2007), and likely form
heteromeric channels between keratinocytes.
The human epidermis expresses up to 7 distinct connexin proteins in overlapping populations
of keratinocytes highlighting the complexity of gap junctional intercellular communication
(GJIC) in this tissue (Di et al., 2001). Two distinct mouse models demonstrated that persistent
epidermal Cx26 expression promoted a hyperproliferative, inflammatory response suggesting
a delicate balance of individual connexins may be required for epidermal health (Djalilian et
al., 2006). A key factor likely involved in regulating keratinocyte differentiation is an
increasing intracellular Ca2+ gradient between keratinocytes of the stratum basale and stratum
granulosum (Adams et al., 2012; Bikle et al., 2012). Gap junction channels are known to pass
signaling molecules such as IP3 that regulate intracellular Ca2+ handling, which may have a
profound influence on the synthesis and assembly of skin barrier components such as filaggrin
and ceramides (Bosen et al., 2015; Sandilands et al., 2009). Furthermore, it is well known that
following cutaneous wounding, multiple connexins including Cx26, Cx30, and Cx43, are
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dynamically regulated within the epidermis suggesting they play a major role in coordinating
wound healing events such as keratinocyte proliferation, migration, and differentiation
(Brandner et al., 2004; Churko and Laird, 2013). In fact, numerous studies employing Cx43
knock-down strategies have demonstrated beneficial wound healing outcomes (Churko et al.,
2012; Coutinho et al., 2003; Ghatnekar et al., 2015; Mori et al., 2006; Qiu et al., 2003) which
strongly promotes Cx43 as a therapeutic target for chronic wounds. Despite the evidence
supporting the influence of connexins on epidermal health, the roles of Cx26 and Cx30 in the
skin are still incompletely understood, particularly in the context of healing wounds.
Several Cx26 mutants, including the S17F mutant, are linked to keratitis-ichthyosis-deafness
syndrome (KIDS); a rare and severe autosomal dominant disease featuring generalized
dry/scaly skin, patchy erythematous keratoderma and palmoplantar keratoderma (Coggshall
et al., 2013). In some cases, frequent cutaneous infections lead to fatal septicemia early in life
(Coggshall et al., 2013). In vitro ectopic expression studies have revealed hyperactive or
“leaky” hemichannels as a likely pathogenic characteristic of KIDS mutants (Garcia et al.,
2015; Lee et al., 2009). Interestingly, the S17F mutant does not form functional gap junction
channels or hemichannels on its own (Garcia et al., 2015; Richard et al., 2002), but rather
forms heteromeric hyperactive hemichannels when co-expressed with wild type Cx26 or Cx43
(Garcia et al., 2015). A transgenic mouse that globally expresses the S17F mutant replicates
several KIDS phenotypes in addition to features typically associated with separate Cx26linked diseases (Schutz et al., 2011). However, because these mice have low viability and it is
still unknown how the mutant specifically affects the epidermis, we generated a tissue-specific
mouse that harbours the S17F mutant in the epidermis (Cx26K14-S17F/+). The A88V Cx30
mutant is known to cause the highly variable Clouston Syndrome (Common et al., 2003); a
rare autosomal dominant disease that presents with PPK, regional hyperpigmentation,
alopecia, nail dystrophy, clubbed fingers, and in some cases hearing loss (Kibar et al., 2000;
Sugiura et al., 2013). The A88V mutant forms a small number of partially functional gap
junctions (Berger et al., 2014) in addition to hyperactive hemichannels that release excessive
ATP into the extracellular space and induce cell death (Essenfelder et al., 2004). A transgenic
mouse that globally expresses the A88V Cx30 mutant (Cx30A88V/A88V) exhibits
hyperproliferative sebaceous glands leading to a greasy coat as well as mild hyperkeratosis of
foot pad skin (Bosen et al., 2014). While numerous abnormal cellular characteristics of Cx26
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and Cx30 mutants have been identified, and several transgenic mice have been generated to
model human connexin-linked skin disorders, the etiology of these diseases as well and their
impact on cutaneous wound healing remains poorly understood.
Therefore, by using our novel Cx26K14-S17F/+ mouse and the Cx30A88V/A88V mouse described in
Bosen et al. (2014), we aimed to assess how Cx26 and Cx30 mutants produce skin disease to
ultimately gain further insight into the role of these proteins in healthy skin. We found that
S17F Cx26, but not A88V Cx30 produced severe PPK, wherein expression of Cx26 as well
as filaggrin was elevated in foot pad skin indicating deregulated differentiation. Moreover,
primary keratinocytes from Cx26K14-S17F/+ mice had reduced gap junctional coupling and
changes in migration. Lastly, both Cx26 and Cx30 mutant mice retain most of the properties
associated with active wound healing.

3.2

Materials and Methods

3.2.1 Genetically-Modified Mice
All animal experiments were approved by the Animal Use Committee at Western University
in accordance with guidelines from the Canadian Council for Animal Care. Cx26K14-S17F/+ mice
(hereafter referred to as S17F/+) were generated in-house, on a mixed C57BL/6 and 129Sv
background. Heterozygous floxed mice (Cx26floxS17F/+ - generated in Schütz et al, (2011) and
obtained from Dr. K. Willecke) were crossed with homozygous keratin 14 Cre mice
(Gjb2tm2.2Kwi/Cnrm, Jackson Labs) which were obtained from Dr. L. Dagnino. S17F/+ mice
express S17F Cx26 heterozygously in basal cells of the epidermis, as well as the oral and
vaginal epithelium (Dassule et al., 2000). Cx30A88V/+ and Cx30A88V/A88V mice, (hereafter
referred to as A88V/+ and A88V/A88V, respectively) were generated by Bosen and
colleagues (Bosen et al., 2014) and obtained from Dr. K. Willecke. Due to the differences in
genetic background between mouse strains, all animal experiments used wild-type littermates
as controls (hereafter referred to as Control). Roughly equal proportions of male and female
mice were used for all experiments.
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3.2.2 Mouse Genotyping
Ear notches at the time of weaning were incubated overnight at 58°C in a proteinase K solution
composed of 0.6 mg of proteinase K (Cat# 25530-049; Invitrogen) dissolved in buffer
containing 20 mM Tris Cl pH 8.3, 50 mM KCl, 2.5 mM MgCl2, and 0.5% Tween 20. The
digested tissue solution was incubated for 10 minutes at 95°C and DNA amplification was
carried out by polymerase chain reaction (PCR). PCR mixtures included 10x PCR buffer (Cat#
1360566; Invitrogen), 50 mM MgCl (Cat# 11392196; Invitrogen), 10 µm dNTPs (Cat# 10297018; Invitrogen), and Platinum Taq polymerase (Cat# 10966-018; Invitrogen). Samples were
run for 40 cycles with the annealing temperature set to 57°C for S17F/+ samples, and 65°C
for the A88V/+ and A88V/A88V samples. PCR products were run on a 2% agarose gel
including 200 µg of ethidium bromide, and gels were visualized under ultra-violet light.

3.2.3 Skeletal Staining
Seven day old mice were euthanized, neatly eviscerated to reveal the skeleton, and the skeleton
was stained according to a modified protocol from (McLeod, 1980). Skeletons were
dehydrated in 95% overnight and fixed in acetone for 24 hours. Skeletons were stained for 4
days using a solution containing 0.015% alcian blue, 0.05% alizarin red, and 5% acetic acid
in 70% ethanol as described in (Wang et al., 2007b). Finally, skeletons were cleared using 1%
KOH in ddH20 until the stained vertebrae and intervertebral disks were clearly visible. Two
animals per genotype were used for skeletal staining.

3.2.4 Micro-Computed Tomography
Micro-computed tomography (µCT) scans of euthanized 3-month-old S17F/+ and control
whole mouse bodies were obtained using the eXplore speCZT µCT scanner (GE Healthcare)
at Robarts Research Institute (London, ON, Canada) to assess the bone structure underlying
the S17F/+ truncated tail or skeletal abnormalities in the digits. Further technical specifications
and image processing techniques are outlined in (Caskenette et al., 2016). Briefly, scans were
acquired with a voxel size of 100 µm3 and 3D composite images were reconstructed and
manipulated using MicroView software (GE Healthcare Biosciences). One S17F/+ and one
control mouse were used to create isosurface images.
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3.2.5 Tissue Lysates and Immunoblotting
Foot pad skin was dissected, frozen with liquid nitrogen, and pulverized with a cold mortar
and pestle over dry ice. Lysates were generated by dissolving the pulverized tissue in 2x
immunoprecipitation buffer (containing 1% Triton X-100, 150 mM NaCl, 10 mM Tris, 1 mM
EDTA, 1 mM EGTA, 0.5% NP-40, 1.0 mg of NaF, 1.0 mg of Na3VO4, and a Complete Mini
protease inhibitor tablet (Roche Cat# 10570500)). Lysates were stored at -80°C until
electrophoresis. Protein concentration was determined with standard bicinchoninic acid assay.
Lysates were run on a 12% polyacrylamide gel using SDS-PAGE and protein was transferred
to nitrocellulose membranes with the iBlot dry transfer system (7 minute transfer). Membranes
were blocked in 2% BSA in PBST and probed with 1:1000 mouse anti-Cx26 (Invitrogen Cat#
138100), 1:1000 rabbit anti-Cx30 (Invitrogen Cat# 71-2200), 1:5000 rabbit anti-Cx43 (Sigma
Cat# 112M4824), 1:5000 mouse anti-GAPDH (Millipore Cat# 2145925), 1:1000 mouse antikeratin 14 (ThermoFisher Cat# MA5-11599), 1:1000 rabbit anti-filaggrin (Covance Cat#
PRB-417P), and 1:400 rabbit anti-proliferating cell nuclear antigen (PCNA) (Santa Cruz Cat#
FL-261:sc-7907) antibodies. Secondary antibodies included AlexaFluor680 (Cat# A21076;
Life Technologies) and IRDye800 (Cat# 24058; Rockland) and membranes were visualized
using the Odyssey infrared imaging system. An unpaired t-test (for S17F/+) or one-way
ANOVA (for A88V/+ and A88V/A88V) was performed on the mean intensity (K counts) of
biological replicates.

3.2.6 Immunohistochemistry and Immunofluorescence Imaging
Foot pad skin was fixed with 10% neutral buffered formalin overnight at 4˚C, paraffin
embedded, sectioned, and stained with hematoxylin and eosin for histological analysis
according to (Stewart et al., 2013). Separate tissue samples were also fixed, cryopreserved in
30% sucrose in PBS, embedded in 1% low melting point agarose containing 18% sucrose and
0.01% NaN3, flash frozen with liquid nitrogen, and cryosectioned for immunofluorescent
imaging. Frozen sections were blocked in 3% BSA + 0.2% Triton X-100 and labeled with
1:400 rabbit anti-Cx26 (Invitrogen Cat# 512800), 1:400 rabbit anti-Cx30, 1:500 rabbit antiCx43, 1:200 mouse anti-keratin 14, 1:200 rabbit anti-filaggrin, and 1:400 rabbit anti-Ki67
(Abcam Cat# ab66155). The secondary antibodies used were 1:500 anti-rabbit Alexa488 (Life
Technologies Cat# A11008), 1:500 anti-rabbit Alexa555 (Life Technologies Cat# A21429),

!

!

63!

and 1:500 anti-mouse Alexa488 (Life Technologies Cat# A11017). Sections were counterstained with Hoechst, mounted using Airvol, and imaged with a Zeiss LSM 800 confocal
microscope equipped with ZenWorks software. Images were captured with a 40x water
immersion objective.

3.2.7 Wound Healing Assays
Three month old mice were anesthetized with isoflurane, administered analgesics
subcutaneously, then a small section of dorsal hair was shaved and depilated with Nair, and
the skin was sterilized using the standard 3-stage preparation. Wounds were performed using
a 5mm human punch biopsy to remove the full thickness of the skin as described in (Churko
et al., 2011b). Briefly, dorsal skin was held taut and a punch biopsy tool was twisted on the
skin with light pressure until a full-thickness circle of skin was removed. Skin tension was
released and allowed to retract for approximately 30 seconds before imaging. Wound
inspection and imaging was performed the day of surgery, and every second day until fully
healed. Wound sizes were measured using ImageJ in a blinded fashion. A two-way ANOVA
was performed on the mean wound area of at least 6 mice per genotype.

3.2.8 Cell Lines
Connexin-rich rat epidermal keratinocytes (REKs) were originally described in (Baden and
Kubilus, 1983) were provided by Dr. V. Hascall. Cells were grown in DMEM (Life
Technologies Cat# 11965-092) supplemented with fetal bovine serum (Gibco Cat# 12484028), 2 mM L-glutamine (Life Technologies Cat# 25030-081), penicillin and streptomycin
according to (Penuela et al., 2007).

3.2.9 Primary Murine Keratinocyte Culture
Keratinocytes were isolated from neonatal mice (P2-P3) according to (Churko et al., 2012)
with minor procedural adjustments. Briefly, complete body skin was carefully dissected from
neonates was rinsed in Ca2+ and Mg2+ free PBS (Invitrogen Cat# 14190-144) containing 5
µg/mL gentamycin (Invitrogen Cat# 15750-060). Skins were floated dermis side down over
1.5 mL of 50 cU/mL dispase (Corning Cat#354235) at 4˚C overnight with gentle rocking. The
epidermis was gently separated from the dermis, minced with sterile scissors, and incubated
in 0.25% trypsin-EDTA (Invitrogen Cat# 25200-056) for ~10 minutes at 37°C. The cell
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suspension was removed and placed into 1.5 mL of Keratinocyte Serum-Free Medium (KSFM) (Invitrogen Cat# 37010-022) supplemented with 1.4 mM CaCl2 and 1.5 mL of stock
trypsin neutralizer solution (Invitrogen Cat# R-002-100), and centrifuged. The pellet was
resuspended in K-SFM supplemented with 0.05 mM CaCl2, poured through a 70 µm cell
strainer (Falcon Cat# 21008-952), and plated in dishes pre-coated with 50 µg/mL collagen I
(BD Biosciences Cat# 354236). The next day, cells were washed 2 times with Ca2+ and Mg2+
free PBS then incubated in K-SFM containing 1.4 mM CaCl2. Cells were used for experiments
between 48-72 hours following initial plating.

3.2.10 Calcein-AM Dye Recovery
Primary mouse keratinocytes and REKs were grown on 35mm glass bottom dishes and preloaded for 10 minutes at 37˚C in a 0.3 mM isotonic glucose solution containing 2 µl/mL
calcein-AM dissolved in DMSO. Cells were washed in PBS and photobleached to 20% of
original fluorescence intensity with a 488 nm argon laser at 50% strength. Images were
subsequently captured every 10 seconds for approximately 10 minutes with a LSM 800 Zeiss
confocal microscope and a 40x water-immersion lens. Image series were exported to ImageJ
and fluorescence recovery of photobleached cells were measured using the Time Series
Analyzer V3 plugin. Fluorescence recovery curves displayed summarized data and a one-way
ANOVA was performed on the area under the curve (AUC) of biological replicates.

3.2.11 Scratch-Wound Assay
Primary mouse keratinocytes were seeded at 1x106 cells per 35 mm gridded dish (Sarstedt
Cat# 83.1800.001). Culture dishes were pre-coated with collagen as previously described and
following 48 hours of incubation in K-SFM containing 1.4 mM CaCl2, cells were rinsed with
Ca2+ and Mg2+ free PBS and scraped with a P1000 pipette tip. Cells were then replenished
with K-SFM containing no supplements or CaCl2 and images of 10 identical sections per dish
(0.5 mm2), were captured at 24 and 48 hours following the scrape. For each image, the gap
between keratinocyte fronts was measured in 5 similar regions and an unpaired t-test (S17F/+
cultures) or a one-way ANOVA (A88V/+ and A88V/A88V cultures) was performed on the
calculated migration distances of replicates.
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3.2.12 Scrape-Load Assay
Primary mouse keratinocytes were seeded at 1x106 cells per 35 mm dish and incubated in KSFM containing 1.4 mM CaCl2 for 48 hours. Cells were washed twice with warm HBSS and
then incubated in HBSS containing 2.5% Lucifer Yellow and 1% DiI. Cells were scraped with
a sharp surgical blade and incubated at 37˚C for 5 minutes. Cells were then washed 3 times
with warm HBSS and images with a Leica inverted epifluorescent microscope using a 20x
objective. Five similar fields were imaged for each experimental replicate. For each image,
Lucifer Yellow transfer distance minus DiI transfer distance was calculated, and a one-way
ANOVA was performed on the calculated means of biological replicates.

3.2.13 Statistical Analysis
Graph Pad Prism version 6 was used for all statistical analysis and statistical significance was
noted when p<0.05. All student’s t-tests were two tailed. All histogram values represent the
mean + SEM.

3.3

Results

3.3.1 Epidermal expression of S17F Cx26, but not A88V Cx30, results in severe
skin features plus comorbidities
S17F/+ mice harbouring the mutated Gjb2 gene only in cells expressing keratin 14 (basal
keratinocytes) resulted in a tissue-defined transgenic mouse that expressed the S17F mutant
under the control of the endogenous Cx26 promoter. This primarily epidermis expression
profile was capable of reproducing KIDS skin features in a novel mutant mouse in addition to
several intriguing phenotypes (Fig. 3.1). S17F/+ pups were visibly smaller and had red, dry,
scaly skin (Fig. 3.1A). PCR analysis of skin tissue confirmed the heterozygous expression of
S17F Cx26 (Fig. 3.1B). Contrary to global Cx26S17F/+ mice (Schutz et al., 2011), our tissuedefined S17F/+ mice had no loss of viability and were born in equal proportion to wild type
littermates (Fig. 3.1C). Interestingly, S17F/+ mice were approximately 15% smaller by 3
months of age (Fig. 3.1E), and had a shortened tail (Fig. 3.1D) which coincided with the
formation of a cutaneous bulb at the distal tail by post-natal day 7 (Fig. 3.1F, G). This appeared
to impair proper vertebral formation within the bulb preventing normal tail growth (Fig. 3.1H).
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Fig. 3.1. S17F/+ mice mimic KIDS skin characteristics and have several additional
phenotypes. (A) S17F/+ neonates were smaller and visually distinguishable from control
littermates. (B) Skin sample PCR amplification confirms the heterozygous expression of S17F
Cx26 in S17F/+ mice. (C) Litters contained equal portions of S17F/+ and control pups with
no loss of mouse viability (n ≥ 148). (D) Representative photos of 3-month-old S17F/+ and
control mice reveal moderate differences in size but a pronounced tail phenotype. (E) Whole
mouse weights at 3 months of age showed S17F/+ mice are ~15% smaller (**p<0.01, N ≥ 17).
(F) Skeletal stains of P7 tails revealed vertebral malformations underlying the tail phenotype
in S17F/+ mice. (G) Cross-section of a distal tail paraffin section stained with hematoxylin
and eosin revealed grossly thickened epidermis. (H) µCT scans of 3-month-old mouse tails
revealed vertebral abnormalities in S17F/+ mice. Red arrows in (H) denote the relative
locations of cross sections in (G).
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Severe PPK was clearly visible in adult S17F/+ mice in which foot pad epidermis displayed
protruding hyperpigmented calluses (Fig. 3.2A). Histological examination confirmed a gross
thickening of vital epidermal layers (stratum basale, spinosum, and granulosum) (Fig. 3.2B).
In addition to the bulbous region at the distal tail, middle regions of tail epidermis also
displayed moderate thickening of these vital layers (Fig. 3.2B).
The Cx30 mutant mice (homozygotes indicated as A88V/A88V and heterozygotes as A88V/+)
were previously described in (Bosen et al., 2014) and reported to have hyperproliferative
sebaceous glands and mild hyperkeratosis of foot pad skin. Besides a greasy matted coat, we
found no cutaneous phenotypes, nor a measureable thickening of foot pad epidermis (Fig.
3.3A).

3.3.2 S17F Cx26, but not A88V Cx30, disrupts keratinocyte differentiation in
foot pad epidermis
Tissue lysates of hind foot pad skin from 3-month-old S17F/+ mice showed elevated levels of
Cx26 (Fig. 3.2C). While no differences in Cx30 or Cx43 levels were detected in mutant
epidermis, all three connexins had large overlapping distribution profiles that were clearly
distinguishable from control epidermis (Fig. 3.2D). Each connexin formed abundant gap
junction plaques indicating that the S17F Cx26 mutant does not impair connexin trafficking
in vivo. S17F/+ epidermis also had normal levels of keratin 14 (expressed in basal
keratinocytes) but a greater amount of filaggrin (expressed in the stratum granulosum and
corneum) which was found in numerous suprabasal keratinocyte layers (Fig. 3.4A, B).
Epidermal proliferation was not affected based on Ki67 (Fig. 3.4C) and proliferating cell
nuclear antigen (PCNA) assessment (Fig. 3.4D). Foot pad epidermis from A88V/+ and
A88V/A88V mice had no changes in epidermal connexin expression level (Fig. 3.3B) or
distribution pattern (Fig. 3.3C). Additionally, A88V/+ and A88V/A88V epidermis were
similar to control epidermis for keratin and filaggrin expression, as well as proliferation (Fig.
3.5). Together these findings suggest epidermal S17F Cx26 but not A88V Cx30 disrupts
keratinocyte proliferation-differentiation balance and promotes the formation of PPK in mice.

3.3.3 Primary keratinocytes harvested from S17F/+ mice exhibit reduced GJIC
and collective cell migration
Keratinocytes were harvested from newborn connexin mutant mice and WT littermates to
assess the influence of physiological levels of S17F Cx26 and A88V Cx30 on keratinocyte
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Fig. 3.2. S17F/+ mice display thicker foot pad and tail epidermis, and deregulated
epidermal connexin expression. (A) 3-month-old S17F/+ mice exhibit severe foot pad
epidermal thickening including abnormal non-squamous keratinocytes in suprabasal layers as
well as thicker tail epidermis compared to controls (B) (unpaired t-test, ***p<0.001,
****p<0.0001, N ≥ 7). (C) Foot pad skin lysates from 3-month-old S17F/+ mice exhibited
elevated levels of Cx26 expression compared to controls (unpaired t-test, **p<0.01, ns =
p>0.05, N ≥ 10). (D) Cryosections of 3-month-old S17F/+ foot pad epidermis revealed that
Cx26, Cx30, and Cx43 formed abundant gap junctions in a broad range of keratinocyte layers.
Complete and dashed lines denote the dermis-epidermis boundary and stratum granulosumcorneum boundary, respectively. Scale bar in (A-upper) = 50µm (inset = 10µm), (A-lower) =
10µm, (D) = 20µm (inset = 20µm).
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Fig. 3.3. A88V/+ and A88V/A88V mice display normal foot pad epidermis and connexin
expression. (A) Foot pad skin from 3-month-old mutant mice displayed normal epidermal
appearance and thickness (ns = p>0.05, N ≥ 5) and no differences in Cx26, Cx30, and Cx43
expression (B) (ns = p>0.05, N = 7). (C) Foot pad skin cryosections from 3-month-old mutant
mice also displayed Cx26, Cx30, and Cx43 formed abundant gap junction plaques (arrows in
insets) and were expression in discrete keratinocyte layers. Complete and dashed lines denote
the dermis-epidermis boundary, and the stratum granulosum-corneum boundaries,
respectively. Scale bar in (A) = 50µm (C) = 20µm, (inset = 20µm).
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Fig. 3.4. S17F/+ mice display abnormal keratinocyte differentiation in foot pad
epidermis. (A) Foot pad skin lysates from 3-month-old S17F/+ mice have elevated filaggrin,
but normal keratin 14 levels compared to controls (**p<0.01, N ≥ 10). (B) 3-month-old foot
pad epidermis labeled for filaggrin (red) and keratin 14 (green) revealed elevated filaggrin
labelling of suprabasal keratinocytes in S17F/+ epidermis. (C) 3-month-old foot pad epidermis
labeled for Ki67 (red) and lysates immunoblotted for PCNA (D) demonstrated unaltered levels
of cell proliferation in S17F/+ epidermis (ns = p>0.05, N ≥ 10). Complete and dashed lines
denote the dermis-epidermis boundary and stratum granulosum-corneum boundary,
respectively. Scale bar in (B) and (C) = 20µm.
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Fig. 3.5. A88V/+ and A88V/A88V mice display normal keratinocyte differentiation and
proliferation in foot pad epidermis. (A) 3-month-old A88V/+ and A88V/A88V foot pad
skin cryosections revealed similar localization of immunolabelled filaggrin (red) and keratin
14 (green) which were also expressed at normal levels in foot pad skin lysates (B) (ns =
p>0.05, N = 7). Foot pad epidermis immunolabelled labelled for Ki67 (C) and lysates
immunoblotted for PCNA (D) displayed unaltered levels of cell proliferation in A88V/+ and
A88V/A88V epidermis (ns = p>0.05, N=7). Scale bar in (A, C) = 20µm.
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and migration. Similar to a well characterized rat epidermal keratinocyte (REK) cell line (Fig.
3.6A), nearly all primary cells labeled thoroughly with keratin 14 and intermediate filaments
were clearly visible under high magnification (Fig. 3.6B), indicating a highly pure
keratinocyte population. In dense clustered regions, cells stratified and increased filaggrin
expression, mimicking the behavior of stratified keratinocytes in live epidermis (Fig. 3.6B).
Keratinocyte cultures were incubated in media containing 1.4mM CaCl2 for 24 hours to
stimulate differentiation and the subsequent expression of Cx26 and Cx30. Compared to
controls, S17F/+ cultures appeared to form fewer and smaller Cx26 gap junction plaques
between cells, and demonstrated reduced fluorescence recovery following photobleaching
(Fig. 3.7A, B). Furthermore, S17F/+ cultures displayed reduced collective migration in
response to scratch wounds (Fig. 3.7C). Keratinocytes from A88V/A88V mice also appeared
to form far fewer Cx26 and Cx30 gap junction plaques compared to A88V/+ and control
cultures (Fig. 3.8A). Interestingly, A88V/A88V keratinocytes displayed no differences in
GJIC yet demonstrated increased collective migration in response to scratch wounds (Fig.
3.8C). Together these findings suggest Cx26 intercellular communication may influence
keratinocyte migration whereas Cx30 may influence migration in a GJIC independent
mechanism.

3.3.4 S17F/+ mice display irregular dorsal skin remodeling and tail skin wound
healing
Since dynamic regulation of Cx26 and Cx30 coincides with different stages of wound healing,
we tested whether mutant Cx26 or Cx30 mutant mice had any overt wound healing defects.
Between 3 and 4 months of age, a punch biopsy of depilated dorsal skin created a wound in
which healing was monitored. S17F/+ mice displayed no differences in wound size at any
stage of recovery (Fig. 3.9A) however, repaired epidermis was measurably thicker in S17F/+
mice suggesting possible aberrant epidermal remodeling in response to the wound (Fig. 3.9B).
No differences in wound healing or abnormalities in repaired epidermis were found in Cx30
mutant mouse dorsal wounds (Fig. 3.9 C, D).
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Fig. 3.6. Isolated keratinocyte cultures are highly pure. Similar to well-characterized REKs
(A), highly pure primary keratinocyte cultures (B) immunolabelled extensively with keratin
14 (green) and demonstrated elevated filaggrin expression in regions where cells began to
stratify (left). Individual keratin filaments were visible under high magnification (right). Scale
bar in (A) = 10µm, (B-left) = 20µm, (B-right) = 10µm.
wherein patients express connexin mutants with defects in cellular communication (van
Steensel, 2004). The epidermis relies on complex GJIC to coordinate a balance of cell
proliferation and differentiation for the maintenance of rapid physiological turnover and
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Fig. 3.7. Keratinocytes isolated from S17F/+ neonates have reduced GJIC and collective
cell migration. (A) S17F/+ keratinocyte cultures appeared to form fewer and smaller Cx26
gap junctions between cells. (B) S17F/+ keratinocytes have reduced calcein-AM fluorescence
recovery after photobleaching compared to controls indicative of reduced GJIC (*p<0.05, N
= 8). (C) Collective keratinocyte migration in response to scratch-wounds was reduced in
S17F/+ cultures compared to controls (***p<0.001, ****p<0.0001, N = 4 separate
experiments). Scale bar in (A) = 20µm (inset = 10µm), (B) = 10µm, (C) = 100µm.
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Fig. 3.8. Keratinocytes from A88V/A88V mice display normal GJIC but increased
collective cell migration. (A) Keratinocytes from A88V/A88V mice appeared to form fewer
gap junction plaques compared to control and A88V/+ keratinocytes. (B) Following scrapeloading, mutant keratinocytes displayed similar Lucifer yellow dye transfer to controls (ns =
p>0.05, N = 4). DiI is a gap junction impermeable tracer to denote keratinocytes at the scrape
edge denoted by the dashed line. (C) A88V/A88V keratinocytes exhibited increased collective
cell migration compared to A88V/+ and control keratinocytes (**p<0.01, ***p<0.001,
****p,0.0001, N = 4). Scale bar in (A) = 10µm, (B) = 20µm, (C) = 50µm.
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Fig. 3.9. Mutant mice display normal wound closure, but S17F/+ mice exhibit abnormal
epidermis remodeling. (A) Dorsal skin wound closure was found to be normal in S17F/+ as
well as A88V/+ and A88V/A88V mice (C), however, epidermis remodeling following wound
closure generated thicker epidermis in S17F/+ mice compared to controls (B) (*p<0.05, N ≥
4). (D) A88V/+ and A88V/A88V mice displayed normal epidermis remodeling following
wound closure. Scale bar in (B, D) = 10µm.
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Discussion

Connexin-linked skin diseases encompass a diverse array of congenital skin abnormalities
resiliency to injury. Of particular interest are Cx26 and Cx30 linked skin diseases due to the
large number of distinct gene mutations that lead to syndromic diseases featuring variable skin
disorders (Martin and van Steensel, 2015). Patients dominantly expressing the S17F Cx26 or
A88V Cx30 mutants are diagnosed with KIDS and Clouston Syndrome, respectively, and
display some dissimilar phenotypes, but share the common characteristic of PPK (Lamartine
et al., 2000; Richard et al., 2002). Although mutant connexins undoubtedly underpin these
diseases, specific pathogenic mechanisms are poorly understood and the question of whether
these patients have wound healing defects has not been explored. In this study, we generated
a novel tissue-specific S17F Cx26 mouse and used the previously described A88V Cx30
mouse (Bosen et al., 2014) to address these questions. We found that our novel Cx26K14-S17F/+
mice displayed severe PPK and importantly, no decrease in viability. Foot pad epidermis of
S17F/+ mice displayed increased Cx26 expression and irregular localization profiles of
epidermal connexins. Furthermore, S17F/+ foot pad epidermis exhibited elevated filaggrin
expression, but normal expression of keratin 14 and displayed normal proliferation. Primary
keratinocytes isolated from connexin mutant neonates displayed altered GJIC and migration
abilities in culture. S17F/+ skin exhibited aberrant epidermal remodeling during wound
healing but wounds healed at a similar rate to littermate control mice. Lastly, A88V/+ and
A88V/A88V mice displayed no epidermal phenotypes or differences in wound healing
compared to controls.
S17F Cx26 was first linked to KIDS in 2002 (Richard et al., 2002) and is now understood to
form non-functional gap junction channels or hemichannels but does form hyperactive
heteromeric hemichannels with wild type Cx26 and Cx43 in culture (Garcia et al., 2015).
Many syndromic Cx26 mutants fail to form functional channels (Xu and Nicholson, 2013),
however studies investigating separate KIDS linked mutants reveal that hyperactive
hemichannels may be a strong etiological factor in KIDS (Garcia et al., 2015; Gerido et al.,
2007; Lee et al., 2009). A mutant mouse globally expressing S17F Cx26 was found to
replicate KIDS skin and hearing phenotypes making it a suitable model for KIDS (Schutz et
al., 2011). However, one drawback with this model was a sharp loss of mouse viability. To
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alleviate this concern and to directly assess the role of the S17F Cx26 mutant in the epidermis,
we generated a conditional mutant mouse which expresses the mutant in cells expressing
keratin 14. We showed here that indeed epidermal expression of S17F Cx26 produced the
severe PPK seen in KIDS, as well as a short, blunted tail reminiscent of autoamputated digits
in patients with the Cx26-linked Vohwinkel Syndrome (Maestrini et al., 1999). Furthermore,
tissue-specific S17F Cx26 mice were generally healthy suggesting that expression of S17F
Cx26 in other tissues such as liver, kidney, brain, and gut may reduce mouse viability.
The nearly universal feature of PPK in connexin-linked skin diseases suggests that proper
GJIC is crucial to maintain highly stratified volar epidermis (Avshalumova et al., 2014). We
found an imbalance of keratinocyte proliferation and differentiation in foot pad epidermis of
S17F/+ mice indicated by increased filaggrin expression yet normal expression of Ki67 and
PCNA. Since filaggrin condenses the keratin cytoskeleton in differentiated keratinocytes, we
surprisingly observed that suprabasal keratinocytes from S17F/+ foot pad skin did not appear
to adopt a squamous morphology like those in control epidermis. We also showed that Cx26,
Cx30, and Cx43 were not confined to specific keratinocyte layers but rather were expressed
in most keratinocytes, further suggesting deregulated differentiation. Calcium homeostasis in
the epidermis is thought to have a large impact on keratinocyte differentiation (Adams et al.,
2012), and since Ca2+ mobilizing molecules such as IP3 and ATP are permissible by gap
junctions and hemichannels, the calcium profile in lesioned epidermis is an attractive, albeit
difficult element to assess. Interestingly, Bosen and colleagues showed that unlike control
littermates, global S17F Cx26 mice exhibited large amounts of Ca2+ in the stratum corneum,
suggesting that S17F Cx26 may disrupt the calcium profile in the epidermis (Bosen et al.,
2015). As some connexin hemichannels are known to release ATP in response to mechanical
stimulation (Bao et al., 2004; Baroja-Mazo et al., 2013; Saez et al., 2005), it is plausible that
mutant connexins in the mechanical environment of volar skin could stimulate aberrant
purinergic signaling that disrupts calcium homeostasis and finally differentiation (BarojaMazo et al., 2013; Martin et al., 2014). Furthermore, lesions of flexural skin regions are also
commonly observed in KIDS and Vohwinkel Syndrome patients (Avshalumova et al., 2014;
Coggshall et al., 2013) further supporting mechanically stimulated Cx26 mutants in skin
pathogenesis. Nevertheless, investigations into the mechanical sensitivity of Cx26 mutants is
warranted to shed light on this notion.
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Keratinocytes isolated from our mice demonstrated that physiological levels of S17F Cx26
led to reduced gap junctional coupling and a similar reduction in collective cell migration.
Following wounding, undamaged keratinocytes at the wound edge initiate re-epithelialization
by migrating under the coagulum (Martin, 1997). During this process, a transient reduction of
cell surface Cx43 favours cell migration by reducing cell-cell adhesion through its binding
partner zona occludens-1, a protein linked to junctional complexes (Mendoza-Naranjo et al.,
2012). Our results suggest that Cx26, which is thought to only bind an ubiquitin-ligase protein
(Henzl et al., 2004), can also influence cell migration through direct intercellular
communication. It is well documented, yet poorly understood why Cx26 and Cx30 are
transiently upregulated in wound edge keratinocytes (Coutinho et al., 2003; Davis et al., 2013;
Goliger and Paul, 1995; Kretz et al., 2003), however our results suggest this may generate a
highly coupled keratinocyte network to optimize collective cell migration. To our surprise,
S17F/+ cultures also appeared to form fewer and smaller gap junction plaques in light of
extensive Cx26 gap junction formation in intact S17F/+ epidermis. Reduced gap junction
formation by S17F Cx26 has however, been reported in HeLa cells (Garcia et al., 2015),
therefore the disparagement of connexin expression between native epidermis and in vitro
models highlights the importance of using mutant mouse models in understanding connexinlinked pathologies.
Because Cx26 is dynamically regulated during wound healing (Brandner et al., 2004) and
KIDS patients develop inflammatory skin lesions (Coggshall et al., 2013), it raises questions
as to whether KIDS patients have abnormal wound healing. There are currently no reports of
KIDS patients exhibiting wound healing defects, however, the protective care these patients
require (Coggshall et al., 2013) and the rare nature of this disease argues that a wound healing
defect may be under reported. In one study linking Cx26 levels to wound healing, two mouse
models with persistent epidermal Cx26 expression developed inflammatory lesions and
wounds which displayed improper remodeling (Djalilian et al., 2006) suggesting that Cx26
may contribute to the inflammatory and remodeling phases of wound healing. However, the
S17F/+ mice used in our study displayed no overt wound healing defects, and if this finding
can be extrapolated to humans, this would suggest that KIDS patients may actually heal
wounds well. That being said, our findings also suggest that the abnormal keratinocyte
differentiation required for epidermal remodeling may result in thicker epidermis in the healed
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skin from KIDS patients. We also demonstrated that hyperkeratotic foot pad epidermis in
S17F/+ mice had elevated levels of Cx26, suggesting that while unchallenged skin was
relatively normal, challenged skin by weight bearing or wound healing may provide the
conditions for S17F Cx26 to disrupt epidermal physiology. Although the exact nature of these
conditions remains uncertain, our findings support the notion that S17F Cx26 disrupts
epidermal homeostasis by deregulating keratinocyte differentiation.
Contrary to our S17F/+ mice, mice globally expressing A88V Cx30 showed almost no
evidence of skin disease, as the only differential elements were found between A88V/A88V
and control primary keratinocytes. Since differences arose only once mutant keratinocytes
were isolated in vitro, this suggests the influence of A88V Cx30 was easily overcome in native
epidermis where other regulatory are likely at play. Despite differences in genetic background,
the striking dissimilarity of disease presentation between our mouse models, which express
functionally similar connexin mutants, suggests that Cx30 may play a minimal role in murine
epidermis. This notion is supported by the observation that adult Cx30 null mice displayed no
obvious cutaneous phenotypes (Dere et al., 2003).
Lastly, Clouston Syndrome is a highly variable disease in humans which suggests that other
genetic predispositions likely play a large part in disease presentation. For example, Clouston
Syndrome patients do not generally have hearing loss, however one patient expressing A88V
Cx30 in addition to a benign Cx26 mutant exhibited mild deafness (Sugiura et al., 2013).
Despite subtle differences between murine and human epidermis, our findings strongly
support the generation and assessment of animal models that mirror connexin-linked diseases.
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General Discussion

A high degree of GJIC is a hallmark of stratified epidermis (Scott et al., 2012). This
communication is, in part, facilitated by Cx26 and Cx30 gap junctions and it is well known
that their proper assembly and function is critical for overall skin health (Martin and van
Steensel, 2015). This thesis compiles the analyses of several connexin-linked skin diseases at
the level of cells and the intact epidermis. Using transgenic mice, primary keratinocytes, and
reference cell lines, we examined the cellular characteristics of Cx26 and Cx30 mutants and
their link to disease. The goal of this work is to elucidate genotype/phenotype relationships of
distinct connexin mutants as they relate to skin disease and to further understand the
contribution of these critical molecules in epidermal physiology. Here, I will establish a
narrative to integrate our findings within the current literature, discuss their clinical
implications, and present questions for continued investigation.

4.1

Learning outcomes from transgenic mice

Limitations to the clinical translatability of cell-based experiments have forced researchers to
develop animal models to better understand, not only the disease-causing features of connexin
mutants, but also the role of connexins in normal skin development, healing, and homeostasis.
Excluding the novel Cx26K14-S17F/+ mouse used in the current study, at least 10 different mouse
models have been generated as tools to investigate disease-linked connexins (i.e. Cx26, Cx30,
Cx30.3, Cx31, and Cx43) in skin physiology (Bakirtzis et al., 2003; Bosen et al., 2014; Churko
et al., 2012; Cogliati et al., 2015; Djalilian et al., 2006; Maass et al., 2004; Mese et al., 2011;
Schnichels et al., 2007; Schutz et al., 2011). Five of these models feature GJB2 modifications
that have helped reveal the pathogenesis of KIDS and Vohwinkel Syndrome (Bakirtzis et al.,
2003; Mese et al., 2011; Schutz et al., 2011), whereby a role was proposed for Cx26 in
epidermal barrier establishment and cutaneous wound healing (Djalilian et al., 2006). In
addition, Cx30 (Dere et al., 2003) and Cx31 (Plum et al., 2001) null mice displayed no
cutaneous phenotypes despite their expression in normal healthy skin. While it may therefore
be compelling to suggest that Cx30 and Cx31 are unlikely candidates for human skin disease,
in fact, mutations in their genes are linked to Clouston Syndrome, KIDS, and
erythrokeratoderma variabilis (Lamartine et al., 2000; Lilly et al., 2016; Richard et al., 1998).
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These findings strongly suggest that the presence of a connexin mutant can lead to more
pathology than the entire absence of the same connexin. Also, the redundancy of GJIC within
the epidermis likely protects the skin from disease when one connexin is ablated. In our current
study, we took the approach of using partially characterized connexin mutants to assess their
impact on the keratinocytes and the epidermis, and further modeled two connexin mutants in
mouse models of human skin diseases.
Within the steadily-solidifying paradigm that the scope of disease manifestation is governed
by the gain- or loss-of function status of Cx26 mutants, we chose to model KIDS using the
S17F mutant. First pass analyses demonstrated that this mutant conformed to the loss-offunction grouping as no functional homomeric gap junction channels or hemichannels could
be observed (Garcia et al., 2015; Lee et al., 2009), however, a careful consideration of gainof-function properties neatly investigated by Isaac Garcia and colleagues first demonstrated
the extended influence of S17F Cx26 on Cx43. Since Cx26 and Cx43 do not normally intermix
in connexons (Gemel et al., 2004), the curious ability of a non-functional Cx26 mutant to
trans-dominantly bind Cx43 and form hyperactive complexes is indeed an odd concept in
connexin biology. Nevertheless, this surprising finding added substantial value to, not only
our understanding of KIDS, but also the study of connexinopathies, since it demonstrated the
legitimacy of considering all possible connexin interactions within each disease context.
Schütz and colleagues took the next step by first introducing the S17F mutant into a mouse
model (Schutz et al., 2011). This mouse exhibited a dysfunctional epidermal barrier, annular
tail restrictions, foot pad hyperplasia, and moderate hearing loss, making it a suitable model
for KIDS (Schutz et al., 2011). However, the global expression of this mutant significantly
reduced mouse viability, suggesting that tissue-specific knock-in of the mutant Cx26 would
be beneficial. Thus, using the Cx26+/floxS17F mouse provided by Dr. Willecke, we crossed it
with a mouse expressing Cre-recombinase driven from the keratin 14 promoter. Herein, we
demonstrated that epidermis specific expression of S17F Cx26 does not reduce mouse
viability. We further showed that our mice had an intact epidermal barrier as evaluated by
using the exact protocol from (Schutz et al., 2011) (refer to Appendix 1). This observation was
surprising and suggested that perhaps S17F Cx26 expression in embryonic tissues may
interfere with the establishment of the epidermal barrier in utero and contribute to their poor
prognosis. Cx26 is indeed expressed in the labyrinth layer of the fetal mouse placenta and
!
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interestingly, Cx26 null embryos die by 11 days post coitum due to a placental defect (Gabriel
et al., 1998). Direct empirical comparison of the development of global mutant and tissue
specific versions of this mouse may shed light on the nature of the barrier defect and loss of
viability in global mutant mice, and could further point to developmental complications in
patients who harbour KIDS mutations. Nevertheless, our novel mutant mouse model allowed
us to evaluate the influence of the S17F Cx26 on the epidermis alone, and whether this
expression profile can disrupt wound healing which involves numerous unaffected cell types
such as fibroblasts, leukocytes, and endothelial cells.
Primary keratinocytes isolated from S17F/+ mice demonstrated reduced migratory capabilities
and brought into question whether the mice may exhibit wound healing defects. We therefore
assessed wound healing using a standard dorsal skin punch biopsy and measured wound
closure over a period of 13 days. While we found no differences in wound closure between
S17F/+ mice and controls, we must acknowledge that wound-edge keratinocytes migrate
beneath the coagulum (Martin, 1997) and were therefore not visible within our assay.
Furthermore, it is understood that murine wound closure is accomplished primarily by dermal
fibroblast contraction to bring wound edges in close proximity, and differs from human
healing which favours keratinocyte re-epithelialization (Reid et al., 2004; Wong et al., 2011).
The Cx30 A88V mutant mouse used in our study also did not display any wound repair
defects. Together, one might conclude that patients harboring either of these connexin
mutations would heal normally from an acute skin wound. To that end, there is no documented
clinical reports that this cohort of patients have acute skin wounding defects but these events
are not routinely reported in clinically studies. Since wound closure is somewhat different
between mice and humans, caution needs to be exercised in translating our mouse findings to
the human populous.
In Chapter 2, we demonstrated that the cellular characteristics of Cx26 mutants could predict
disease outcomes. Our findings suggested that mutations at highly conserved amino acid
residues (N54K and S183F) can affect connexin binding and trafficking and are linked to
moderate skin diseases. In addition, mutations that interfere with properties of the channel
pore (N14K and D50N) led to cell death in culture and are linked to inflammatory skin
diseases. While we could not determine that cell death was driven by mutant hyperactive
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hemichannels, there is a body of literature that supports their contribution to cell death as well
as inflammation (Essenfelder et al., 2004; Garcia et al., 2015; Gerido et al., 2007; Lee et al.,
2009; Levit and White, 2015). This alludes to the question of how hyperactive hemichannels
may promote inflammation in live epidermis. Conceptually, it can be surmised that since
hemichannels are conduits for molecular exchange between the cytosol and extracellular
milieu, their aberrant activity can radically disrupt the extracellular concentration of
permissible molecular messengers, including inflammatory mediators. Mechanistically, a
study demonstrated that Cx26-expressing human keratinocytes, generated a strong ATP
release response following acute exposure to peptidoglycan (PGN) harvested from the
opportunistic pathogen, S. aureus (Donnelly et al., 2012). Furthermore, they showed that PGN
challenged keratinocytes expressing KIDS mutants generated even stronger ATP responses
and led to exaggerated interleukin-6 release, demonstrating the interaction between KIDS
mutant hemichannels, purinergic signaling, and inflammation. Finally, these responses were
abolished by the connexin channel blocker, carbenoxolone (Donnelly et al., 2012). In addition
to forming non-functional gap junctions, S17F Cx26 was shown to potently inhibit
intercellular dye transfer in cells co-expressing Cx43 (Garcia et al., 2015). This supports our
finding that S17F/+ primary keratinocytes demonstrated reduced gap junctional coupling.
While hyperactive hemichannels have been strongly linked to the inflammatory nature of
KIDS, we wondered if reduced GJIC also contributed to the skin phenotype observed in our
mice. Fortunately, we can begin to address this question by examining the findings from a
mouse that was generated to model human Vohwinkel Syndrome by expressing D66H Cx26
in suprabasal keratinocytes (Bakirtzis et al., 2003). This mutant is not associated with
hyperactive hemichannels, however, similar to S17F Cx26, it inhibits Cx26 and Cx43
mediated GJIC (Rouan et al., 2001). The D66H Cx26 mouse is the only Cx26 mutant mouse
to model a non-inflammatory skin disease and displays scaling skin with a dense, thick corneal
layer (Bakirtzis et al., 2003). In addition, Cx26 and Cx30 were highly intracellular in
suprabasal keratinocytes of mutant epidermis and resulted in increased DNA fragmentation
suggesting that reduced keratinocyte GJIC may deregulate terminal differentiation
(cornification) (Bakirtzis et al., 2003). Empirical comparison of hyperkeratotic lesions from
the D66H Cx26 mouse and KIDS mice (S17F and G45E Cx26) may shed light on the influence
of loss-of-function versus gain-of-function mutants in vivo.
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Taken together, our findings and the literature involving Cx26 mutants and Cx26 mutant mice,
suggest that reduced GJIC via intracellular connexin retention or reduced gap junction
function may result in deregulated keratinocyte differentiation and abnormal skin phenotypes.

4.2

Therapeutic strategies for connexin linked skin diseases and wound
healing

Over a decade of applied research towards connexin-based therapies has generated potential
improvements for the treatment of several chronic health complications such as
neuroinflammatory disorders, vasculopathies, ocular disorders, and notably, chronic skin
wounds (Becker et al., 2016). Using in vitro and animal models of wound healing, some
researchers have developed successful connexin-based strategies to improve wound healing
and as a result, have spurred spinoff companies to commercialize novel connexin therapeutics
(Becker et al., 2016; Ghatnekar and Elstrom, 2013). Of note, Cx43-targeted therapeutic
compounds developed by CoDa Therapeutics and FirstString Research have delivered
promising improvements for the healing of chronic venous and diabetic leg ulcers (Ghatnekar
and Elstrom, 2013) (clinical results update from CoDa). The vast majority of connexin-based
therapeutics focus on Cx43 largely due to the wealth of prior research demonstrating its
involvement in many chronic and acute disease states (Nakase et al., 2004; Ormonde et al.,
2012; Sutcliffe et al., 2015; Wang et al., 2007a). CoDa Therapeutics is developing strategies
to target both Cx43 protein translation using antisense oligodeoxynucleotides, and Cx43
channel function using targeted mimetic peptides or non-specific small molecules such as
HCB1019 (Becker et al., 2016). FirstString Research is another company highly focused on
targeting the C-terminal tail of Cx43 to modulate its function with the intent of improving
chronic wound healing (Becker et al., 2016; Ghatnekar and Elstrom, 2013).
To date, there are no targeted therapies for Cx26 or Cx30-linked skin disease and the current
clinical treatments rely mainly on early diagnosis and management; especially for severe
diseases such as KIDS (Coggshall et al., 2013). Maintenance of the skin barrier is of upmost
importance for such patients since infectious and inflammatory complications are common
and can be life-threatening (Coggshall et al., 2013). Therefore, patients must treat
hyperkeratotic plaques with keratolytic and retinoid compounds, frequently moisturize the
skin, and generously apply antibiotic and antifungal agents (Coggshall et al., 2013; Levit and
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White, 2015). However, some studies have demonstrated that certain clinically approved small
molecules such as mefloquin, carbenoxolone, and benzopyran have the ability to block Cx26
channels demonstrating their potential for therapeutic impact (Cao and Zheng, 2014; Donnelly
et al., 2012; Levit et al., 2015; Levit and White, 2015). Indeed, the greatest therapeutic value
may come from attenuating hemichannel activity since their link to diseased states is well
outlined (Levit and White, 2015), yet their contribution to normal skin physiology is largely
undetermined. There are, however, no clinical trials for any such therapies due to the
inadequate number of recruitable patients (Levit and White, 2015). Fortunately for S17F Cx26
KIDS patients, the Cx43-targetted therapies from CoDa and FirstString may in fact provide
clinical relief due to the specific involvement of Cx43 in their pathophysiology. In addition,
the connexin mimetic peptide, Gap19, which targets the intracellular loop of Cx43, inhibits
Cx43 hemichannels without affecting GJIC as shown in astrocytes (Abudara et al., 2014). It
would certainly be interesting to assess its effectiveness in S17F Cx26 expressing
keratinocytes, as perhaps aberrant heteromeric hemichannels may be neutralized without
disrupting normal Cx43 function.
As evidence builds for the impact of Cx26 on wound healing, we may begin to see Cx26targeted therapeutics emerge in applied clinical research. Since abnormal expression of both
Cx26 and Cx43 has been established in non-healing diabetic wounds (Becker et al., 2012;
Wang et al., 2007a), there may be considerable therapeutic value in pursuing Cx26-targeted
wound therapies, which would undoubtedly provide sufficient patient numbers to organize
clinical trials. In addition, such therapies may provide relief for patients with congenital Cx26linked diseases.
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Appendix 1
Cx26K14-S17F/+ mice have an intact epidermal barrier
One of the principle functions of the skin is to provide a protective barrier from environment
insults including UV radiation and opportunistic pathogens, and to limit water loss. As a first
pass assessment for water barrier function, a toluidine blue barrier penetration assay was
performed. Katanya C. Alaga and I contributed equally to this work.

Methods
The barrier assay was performed exactly as described in (Schutz et al., 2011). Briefly, P1 pups
were CO2 euthanized and put through a series of increasing concentration methanol washes,
followed by decreasing concentration methanol washes. Pups were then stained for 15 minutes
in an aqueous 0.2% toluidine blue solution. Following staining, the pups were washed several
times in 90% ethanol, dried, and imaged with an iPhone5. Areas of dark blue/purple staining
indicated toluidine blue dye penetration and therefore a non-functional water barrier. A
positive control was performed by making a small laceration to the skin.

Results
We found that similar to littermate controls, S17F/+ epidermis did not stain blue indication
little to no epidermial penetration of the water soluble dye. However, epidermal staining was
evident in areas of the skin that had ben cut, or treated with acetone which disrupts lipids in
the epidermal barrier (Tsai et al., 2001). This suggests that neonatal S17F/+ epidermis indeed
forms an effective water barrier.
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Figure A1. P1 neonates were euthanized and submerged in an aqueous 0.2% toluidine blue
solution for 15 minutes. The absence of epidermal staining of both S17F/+ and controls
indicates a functional epidermal barrier. A small incision and treatment with acetone were
used as a positive control.
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Appendix 2
Permissions for Artwork Reproduction
Dr. Jared Churko, a former PhD student in Dr. Dale Laird’s lab, generated a graphic to depict
the expression of several connexins in adult mouse epidermis. Since I used this graphic in
Chapter 1 of this thesis, I have included here his written permission from our email
conversation.
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Appendix 3
Animal Use Protocol Approval
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